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ABSTRACT 
 
Constrictor Prostanoid-Potentiated Vascular Contraction: Regulation of Endothelial and 
Vascular Smooth Muscle Mechanisms by Estrogen. (May 2004) 
Min Li, B.M.S., Beijing Medical University 
Chair of Advisory Committee: Dr. John N. Stallone 
 
The objectives of this research were to elucidate the involvement of constrictor 
prostanoids in the vascular reactivity to vasopressin (VP) and the role of estrogen in the 
regulation of the constrictor prostanoid mechanism in the female rat. Aortas obtained 
from male, intact (InT)-, ovariectomized (OvX)- and OvX + estrogen-replaced 
(OvX+Est)-female rats were studied.  Contractile responses to VP were examined in the 
presence of nonselective and selective cyclooxygenase (COX) inhibitors. Basal and VP-
stimulated release of thromboxane A2 (TxA2) and prostacyclin (PGI2) from the aortic 
wall were measured. Concentration-response curves to exogenous TxA2 were also 
obtained. To elucidate the regulatory effects of estrogen on the constrictor prostanoid 
pathway, the expression of COX-1, COX-2, thromboxane synthase (TxS) and 
thromboxane receptor (TP) mRNA were detected by reverse transcription-polymerase 
chain reaction (RT-PCR). Further, immunohistochemistry was employed to determine 
COX-1, COX-2 and TxS protein expression in aortic endothelium and vascular smooth 
muscle. 
The major findings of this research are that: 1) The contractile responses of the 
female rat aorta to VP were enhanced by COX-2-mediated production of constrictor 
iv  
prostanoids (PGH2/TxA2), and this mechanism is potentiated by estrogen; 2) Vascular 
reactivity to exogenous TxA2 was higher in the female than in the male rat aorta, and 
OvX attenuated and estrogen replacement therapy restored vascular reactivity to TxA2 in 
the female aorta; 3) VP-stimulated release of endogenous TxA2 and PGI2 were higher in 
the female than in the male rat aorta, and OvX attenuated and estrogen replacement 
therapy restored VP-stimulated release of these endogenous prostanoids by the female 
aorta; and 4) The expression of COX-2 and TxS mRNA and protein, and the expression 
of TP mRNA were higher in InT-female than in male, and were reduced by OvX and 
restored by estrogen replacement therapy. 
In conclusion, estrogen potentiated contractile responses of the female rat aorta 
to VP by upregulating the expression of COX-2, TxS and TP; thereby enhancing VP-
induced release of TxA2, as well as the vascular reactivity to endogenous TxA2. 
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CHAPTER I 
INTRODUCTION 
 
Epidemiological studies have revealed that the incidences of cardiovascular 
diseases, principally coronary artery disease and hypertension, are lower in 
premenopausal women than in men, but that after menopause, these diseases increase in 
women to levels similar to those of men (6, 12, 85, 223). These observations suggest that 
female gonadal steroid hormones may exert protective effects on the cardiovascular 
system. Human clinical and animal experimental studies have demonstrated that 
estrogen decreases serum cholesterol levels (260), stimulates growth of vascular 
endothelium (165), inhibits growth of vascular smooth muscle (VSM) cells (21, 130), 
and induces release of the local vasodilators such as nitric oxide (NO) (98, 259) and 
prostacyclin (PGI2) (171). However, large-scale hormone replacement therapy (HRT) 
studies do not show an overall beneficial effect of estrogen in postmenopausal women 
(94, 95, 105, 113, 215). In fact, in the first year of HRT (combination estrogen and 
progesterone), the incidence of deleterious cardiovascular events increased. Further, 
premenopausal women are more likely to develop diseases that are primarily vascular in 
origin, such as primary pulmonary hypertension, Raynaud’s disease and some forms of 
migraine headache. These data suggest that estrogen also may exert deleterious effects 
on the cardiovascular system. Animal studies suggest that estrogen enhances vascular 
____________ 
This dissertation follows the style and format of American Journal of Physiology Heart 
and Circulatory Physiology. 
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reactivity to vasopressin (VP), phenylephrine (PE), noradrenaline (70, 168), and that 
cyclooxygenase (COX) metabolites contribute to the estrogen-mediated increases in 
vasoconstriction (70, 159, 225).  Epidemiological and clinical data suggest that vascular 
thromboxane A2 (TxA2) may be the common mechanism underlying the vascular 
diseases more prevalent in women (13, 37, 208). Therefore, in the present studies, the 
role of estrogen in the regulation of arachidonic acid metabolism and vasoconstrictor 
mechanisms will be examined. These studies will focus on the effects of estrogen on 
constrictor prostanoid-potentiated VSM reactivity to VP and interactions between VSM 
and the vascular endothelium. 
These doctoral studies will further clarify male-female differences in vascular 
function and elucidate the underlying mechanisms as well as the controversial effects of 
estrogen on vascular function. These studies also may lead to more effective treatments 
for hormone-dependent cardiovascular diseases in women.  
 Table 1 summarizes the major abbreviations used in this dissertation. 
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Table 1. Major abbreviations used in dissertation.                                                                 
Abbreviation 
 
Explanation Abbreviation Explanation 
AA Arachidonic acid AC Adenylyl cyclase 
ACE Angiotensin converting 
enzyme 
Ach Acetylcholine 
AF Activation function AT Angiotensin receptor 
ANG Angiotensin BK bradykinin 
COX Cyclooxygenase DAG diacylglycerol 
E Epinephrine EDHF Endothelium-derived 
hyperpolarizing factor 
EP Prostaglandin E2 receptor ER Estrogen receptor 
ERE Estrogen response element ET Endothelin receptor 
F Female GC Guanylyl cyclase 
HDL High-density lipoprotein HERS Heart and Estrogen/ 
progestin Replacement 
Study 
HRT Hormone replacement 
therapy 
Indo Indomethacin 
InT Intact IP Prostacyclin receptor 
IP3 Inositol 1,4,5-triphosphate KHB Krebs-Henseleit-
bicarbonate solution 
M Male MAPK Mitogen-activated protein 
kinase 
MI Myocardial infarction NE Noreprinephrine 
NO Nitric oxide NOS Nitric oxide synthase 
NS NS-398 OvX Ovariectomy 
OvX+Est Ovariectomy plus estrogen 
replacement 
PES Prostaglandin 
endoperoxide synthase 
PG Prostaglandin PGH2 Prostaglandin 
endoperoxide 
PGI2 Prostacyclin PIP2 Phophatidylinositol (4,5)-
bisphosphate 
PKA Protein kinase A PLC Phospholipase C 
RAS Renin-angiotensin system RIA Radioimmunoassay 
RT-PCT Reverse transcription-
polymerase chain reaction 
SERM Selective estrogen 
receptor modulator 
SHR Spontaneous Hypertensive 
Rats 
TP Thromboxane receptor 
TxA2 Thromboxane A2 TxB2 Thromboxane B2
TxS Thromboxane synthase VP Vasopressin 
4  
CHAPTER II 
LITERATURE REVIEW 
 
2.1. Sexual dimorphism in vascular diseases 
Epidemiological studies have established that prominent sexual dimorphism 
exists in a variety of human vascular diseases. Pulmonary hypertension, migraine 
headache, and Raynaud’s Disease all occur more frequently in premenopausal women 
than in men. These findings suggest that female gonadal steroid hormones may 
exacerbate certain vascular diseases.  
Pulmonary hypertension is diagnosed as a variety of conditions that lead to the 
elevation of pulmonary arterial pressure (252). The cause of the disease is unknown. In 
young and middle-aged women, the incidence of primary pulmonary hypertension is 1.7-
3.5 times that in men (73). These observations suggest that female gonadal steroid 
hormones may contribute to the pathogenesis of this disease. This hypothesis is 
supported by reports that women taking oral contraceptives have a higher risk of 
developing pulmonary hypertension (107, 128). 
Migraine headache is characterized by repeated or recurrent headache, associated 
with temporary increases in the tone of the scalp and neck arteries that supply blood and 
oxygen to the brain (207). Migraine headaches affect about 6 out of every 100 people, 
and are a common type of chronic headache. The ratio of women to men who develop 
migraine headache is 3:1 (194), again implicating female gonadal steroid hormones in 
this disease. 
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Raynaud’s disease is a disorder that affects blood vessels in the fingers, toes, ears, 
and nose. This disorder is characterized by episodic attacks, called vasospastic attacks, 
which cause the blood vessels in these regions to constrict abnormally. Although 
estimates vary, recent surveys show that Raynaud's phenomenon may affect 5 to 10 
percent of the general population in the United States. Women are more likely than men 
to develop the disorder and the incidence in female varies from 4 to 7.1 times that in 
male (14, 25, 87, 251). 
Sex differences observed in these vascular diseases suggest that female gonadal 
steroid hormones may exert deleterious effects on the vasculature that contribute to the 
development of these disorders; however, other observations suggest that female gonadal 
steroid hormones also exert protective effects on the cardiovascular system. For example, 
premenopausal women have a low incidence of coronary heart disease, and after 
menopause, the incidence increases to levels observed in men (6, 12, 85, 223). 
Interestingly, the Heart and Estrogen-progestin Replacement Study (HERS) showed no 
overall benefit of estrogen replacement therapy. In fact, untoward cardiovascular events 
increased significantly in the first year of the study (94, 95, 105). Another study that 
compared 83 women with acute myocardial infarction (MI) who were younger than 46 
years old and 154 controls showed a strong positive association between MI and oral 
contraceptive or other estrogen use (111). The use of oral contraceptives also increases 
the risk of thrombosis (17, 52). The controversy surrounding observations of sexual 
dimorphism in cardiovascular diseases has stimulated investigators to study sexual 
dimorphism in vascular function, the effects of female gonadal steroid hormones on the 
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cardiovascular system, and the underlying mechanisms of ovarian steroid hormone 
actions on the cardiovascular system. 
 
2.2. Mechanisms of vascular reactivity 
The overall mechanisms of VSM contraction will be reviewed first, followed by 
an overview of the mechanisms that regulate vascular tone. This information will form 
the basis for a discussion of the current understanding of male-female differences in 
vascular reactivity.   
 
2.2.1. Mechanism of vasoconstriction 
Contraction of VSM ultimately involves an increase in the intracellular cytosolic 
free Ca2+ concentration (112). Neural, humoral or other stimuli can cause Ca2+ influx 
from the extracellular fluid via sarcolemmal membrane Ca2+ channels and/or cause 
internal Ca2+ release from the sarcoplasmic reticulum. In turn, the increased cytosolic 
Ca2+ binds with the regulatory protein calmodulin, and the calcium-calmodulin complex 
can then activate the enzyme myosin light-chain kinase, which phosphorylates myosin. 
Phosphorylated myosin then interacts with actin to form crossbridges and cause VSM 
shortening (contraction). Relaxation is accomplished by active removal of Ca2+ from the 
cytosol by extrusion across the plasma membrane and by sequestration back into the 
sarcoplasmic reticulum.  
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2.2.2. Regulation of vascular tone 
Blood vessel diameter is regulated by numerous mechanisms and mediators, 
including neural, circulating humoral substances, VSM autoregulation, local metabolites, 
and local humoral substances produced by the vascular endothelium and/or VSM.  
 
2.2.2.1. The role of vascular endothelium in regulating vascular tone 
Vascular endothelial cells produce many vasoactive substances that cause 
vasoconstriction or vasodilation of the underlying smooth muscle. The most important 
endothelium-derived vasodilator is nitric oxide (NO). Other important vasodilators 
include prostacyclin, bradykinin (216), and endothelium-derived hyperpolarizing factor 
(EDHF) (1, 15) (Fig. 1).  
NO is formed from the guanidine nitrogen of L-arginine by the enzyme NO 
synthase (NOS). There are three isoforms of NOS: neuronal (nNOS), inducible (iNOS) 
and endothelial (eNOS). eNOS is Ca2+-calmodulin dependent and constitutively 
expressed in vascular endothelium, cardiac myocytes, blood platelets and other tissues. 
NO activates guanylyl cyclase (GC) in VSM cells, leading to an increase in intracellular 
cyclic GMP (cGMP) level, which causes vasodilation (210). The synthesis and release of 
NO by eNOS can be stimulated by sheer stress on the vascular endothelium, increased 
intracellular Ca2+ in endothelium, and vasoconstrictor or vasodilator agonists that 
interact with the endothelium. Substances such as VP, acetylcholine (ACh), 
catecholamines and substance P all interact with their respective endothelial receptors to  
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Fig. 1. Endothelium-derived vasodilator factors. Sheer stress and various chemical and 
humoral substances evoke the release of nitric oxide from endothelium. NO then 
increases cGMP level in the vascular smooth muscle (VSM) cell, which causes 
vasodilation. The endothelium also produces prostacyclin, which increases cAMP level 
in the VSM cell, which causes vasodilation. Endothelium-derived hyperpolarization 
factor (EDHF) is another vasodilator, which acts by opening potassium channels. NO, 
nitric oxide; ACh, acetylcholine; VP, vasopressin; E, epinephrine; NE, norepinephrine; 
PGI2, prostacyclin; EDHF, endothelium-derived hyperpolarization factor; BK, 
bradykinin. 
 
 
 
activate eNOS and mediate agonist-induced release of NO (210, 216). Under normal 
conditions, NO is a major determinant of local vascular tone (163). 
Endothelium-derived vasoconstrictors include endothelin-1, prostaglandin 
endoperoxide (PGH2), TxA2, angiotensin II (ANG II), and superoxide anions (120, 244) 
(Fig. 2).   
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Fig. 2. Endothelium-derived vasoconstrictor factors. Angiotensin converting enzyme 
(ACE) converts angiotensin I (ANG I) to angiotensin II (ANG II), which acts on 
angiotensin receptor (A) and cause vasoconstriction. ANG I, ANG II, arachidonic acid 
(AA), superoxide anion (O2. -), 5-hydroxytryptamine (5-HT) and substance P (SP) can 
activate the cyclooxygenase (COX) pathway to produce prostaglandin H2 (PGH2) and 
thromboxane A2 (TxA2), which act on their receptor (PGH2/TXA2 receptor) and cause 
vasoconstriction. Production and secretion of endothelin can be activated by ANG II, 
vasopressin (VP), transforming growth factor beta (TGFβ) and thrombin. Endothelin 
then interacts with its VSM receptor (ET) to cause vasoconstriction. 
 
 
Endothelial dysfunction appears to be involved in the pathogenesis of a number 
of cardiovascular diseases. It was reported that during the development of cardiovascular 
diseases the synthesis and release of NO is blunted (31, 139, 238), while the production 
of other relaxing and contracting factors also may become imbalanced (156, 205). For 
example, the vasodilatory response of the brachial artery to ACh is reduced in patients 
with essential hypertension compared to normotensive controls, and infusion of the NOS 
inhibitor L-NMMA into the brachial artery of hypertensive subjects produces a 
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significantly smaller decrease in basal blood flow compared to normotensive controls, 
suggesting that basal release of NO is deficient in hypertensive patients (185). Similarly, 
in patients with pulmonary hypertension, the ratio of TxB2 to 6-keto-PGF1α in plasma is 
increased (13). Further, radioimmunoassay studies showed that 24-hour excretion of 11-
dehydro-thromboxane B2 (a stable metabolite of TxA2) is increased in patients with 
primary pulmonary hypertension and secondary pulmonary hypertension, as compared 
with normal controls, whereas the 24-hour excretion of 2,3-dinor-6-keto-prostaglandin 
F1α (a stable metabolite of prostacyclin) is decreased in hypertensive patients (37). 
 
2.2.2.2. Circulating vasoactive substances 
Vasopressin (VP) is synthesized in the magnocellular neurosecretory cells in the 
paraventricular and supraoptic nuclei of the anterior hypothalamus (74, 199). It is stored 
in the posterior pituitary until the osmoreceptors in the anteroventral portion of the third 
ventricle sense an increase in plasma osmolality and activate the release of this hormone 
(24). Reductions in arterial blood pressure and/or blood volume are also potent stimuli 
for the release of VP. There are two major groups of receptors that can effect changes in 
VP release in response to changes in blood volume and arterial pressure, i.e., stretch 
receptor in the atria of the heart, which respond to changes in atrial volume; and the 
arterial baroreceptors, which respond the sufficient changes of blood volume (78). VP is 
also known as antidiuretic hormone. There are three subtypes of VP receptors: V1a, V1b, 
and V2 (23). The V2 VP receptor, found principally in the kidney, activates adenylyl 
cyclase (AC) via stimulatory G-protein (Gs) and promotes the insertion of aquaporin-2 
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water channels into the luminal surface of the renal collecting tubules, thereby increasing 
water permeability and reabsorption of water from the urine (53, 57). The V1b receptor, 
located on corticotroph cells of pituitary, activates phospholipase C (PLC) and 
stimulates the release of adrenocorticotropin (ACTH) from corticotroph cells of the 
anterior pituitary (3). The V1a VP receptor, located principally on VSM cells, activates 
phospholipase C by interaction with a membrane-associated G protein (Gq/11) and 
thereby causes vasoconstriction (Fig. 3). 
Under normal conditions, the vasoconstrictor effect of VP does not participate in 
the daily regulation of vascular tone; rather, it appears to function mainly in short-term 
(acute) and long-term (chronic) control of blood pressure in hypovolemic/hypotensive 
states such as hemorrhage or dehydration (145). 
Angiotensin II (ANG II) is produced both systemically and locally within the 
vascular wall. Systemically, angiotensinogen is synthesized in liver, released into 
circulation, and interact with renin that is released from the kidney into the circulation. 
Renin catalyzes the conversion of angiotensinogen into angiotensin I (ANG I). 
Angiotensin converting enzyme (ACE), present in the lung and other vascular tissue, in 
turn then converts circulating ANG I into ANG II. Several studies have confirmed that 
renin, angiotensinogen, ACE and ANG II are present in blood vessel walls (60, 61). In 
the human heart, ANG II is also formed by Chymase, an ACE-independent pathway 
(243). Systemic ANG II plays roles in both short-term (acute) and long-term (chronic) 
regulation of arterial blood pressure. Its production is increased in response to  
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Fig. 3. Coupling mechanisms of the V1 and V2 vasopressin receptors (V1R and V2R, 
respectively). The left-hand figure represents a hypothetical cell containing V1R 
(vascular smooth muscle cell) and the right-hand figure represents a hypothetical cell 
containing V2R (renal collecting tubule cell). Binding of V1R by VP promotes the 
dissociation of Gq-GTP. The αq-subunit stimulates PLCβ activity and then promotes 
hydrolysis of PIP2, which increases the intracellular levels of DAG and IP3; IP3 in turn 
stimulates the IP3R that resides in the membrane of the ER and promotes Ca2+ release 
from intracellular stores. Gq also activates receptor-opened calcium channel (ROC). The 
right-hand figure summarizes the V2R associated signaling in the principal cells of the 
renal collecting duct; the occupied receptor promotes dissociation of Gs-GTP into it’s βγ 
and α subunits; the α subunit stimulates AC activity which subsequently increases 
cAMP level. cAMP then activates PKA and the insertion of the preformed water channel 
into the luminal surface of the cell. Abbreviations: AC, adenylyl cyclase; DAG, 
diacylglycerol; ER, endoplasmic reticulum; PIP2, phosphatidylinositol (4,5)-
bisphosphate; PKA, protein   kinase A; PKC, protein kinase C; PLCβ, phospholipase Cβ.  
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hypotension, hypovolemia, hemorrhage, and severe heart failure. In addition to the 
circulating renin-angiotensin system (RAS), local, tissue-generated angiotensin is also 
reported to exist, and may contribute to long-term cardiovascular homeostasis (143, 
230).  
Angiotensin not only vasoconstricts blood vessels acutely, but also stimulates 
VSM cell growth, and appears to participate in the pathogenesis of vascular diseases 
such as hypertension, atherosclerosis and restenosis (62). There are two subtypes of 
angiotensin receptors (AT): AT1 and AT2. The AT1 receptor activates PLC and produces 
inositol 1,4,5-triphosphate (IP3) and DAG. IP3 increases cytosolic Ca2+ concentration by 
stimulating the release of Ca2+ from the endoplasmic reticulum. The AT1 receptor is 
responsible for vasoconstriction, aldosterone and VP release, sodium and water retention 
and sympathetic facilitation (51, 118). The AT2 receptor is expressed at very high levels 
in the developing fetus, whereas its expression is very low in the cardiovascular system 
of the adult. The expression of the AT2 receptor can be modulated by pathological states 
associated with tissue remodeling or inflammation. AT2 receptor stimulation inhibits 
cardiac fibroblast growth and extracellular matrix formation and exerts a negative 
chronotropic effect (102). The signaling mechanism of the AT2 receptor has not been 
well defined, but at least involves the activation of protein tyrosine phosphatase (102). 
Angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor antagonists 
are widely used to treat cardiovascular diseases (56, 72). 
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2.2.3. Synthesis, metabolism and function of prostaglandins 
2.2.3.1.Arachidonic acid metabolism 
Arachidonic acid (AA) is the most common fatty acid present in the 
phospholipids of the mammalian cell membrane. It is released from cell membrane 
phospholipids by the enzyme phospholipase A2 and diacylglycerol (DAG) lipase (150). 
The main routes of metabolism of AA are (Fig. 4): (1) the cyclooxygenase (COX) 
pathway, which produces the prostaglandins (PGs); (2) the lipoxygenase pathway, which 
gives rise to the leukotrienes and several hydroperoxides (HPETEs); and (3) the 
cytochrome P-450 pathway, which forms the P450-eicosanoids (33, 162, 176).  
 
Fig. 4. The metabolic pathway of arachidonic acid. 
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The products of AA metabolism, especially via the COX and cytochrome P-450 
pathways, play important roles in regulating the cardiovascular system. For example, 
various PGs function either as vasodilators or vasoconstrictors, and either as pro-
coagulant or anti-coagulant substances, to regulate vascular tone and the maintenance of 
homeostasis (162, 176). Further, cytochrome P-450 mediates the release of EDHF, 
which cause vasodilation and therefore regulates vascular tone, especially in the 
coronary and renal arteries. In contrast, 20-hydroxyeicosatetraenoic acid (20-HETE), 
another cytochrome P-450 product, is a vasoconstrictor, particularly in the kidney (69, 
201, 269).   
 
2.2.3.2. Cyclooxygenase 
In 1991, it was confirmed that there are two isoforms of COX: COX-1, and 
COX-2 (137, 264). They are encoded by different genes (131, 132). COX-1 is the 
constitutive form of the enzyme, and is present in many cells. In platelets, the only 
detected isoform is COX-1 (245). The analysis of the promoter of the human COX-1 
gene suggests that COX-1 is a housekeeping gene (255). PGs produced by COX-1 
regulate basal cell activities, such as platelet-dependent homeostasis, gastric mucosal 
integrity, and regulation of renal blood flow (219). In contrast, COX-2 was previously 
considered to be an inducible form, present at very low or undetectable levels in most 
quiescent cells, and strongly induced mainly by cytokines, growth factors, and tumor 
promoters (46, 154, 214). Recent studies, however, reveal that COX-2 is also 
constitutively expressed in some tissues such as kidney, brain, spinal cord, lung and 
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heart, and is responsible for regulating tissue functions under various physiological 
states (180, 186, 254). 
Some studies suggest that COX-2 may not just augment the biosynthesis 
mediated by COX-1; rather it may have different functions independent of COX-1. 
Murakami et al. showed that mouse bone marrow-derived mast cells expressed both 
COX-1 and COX-2 at the same time, but IgE-stimulated release of PGD2 was coupled to 
COX-1 activity, while cytokine-induced PGD2 was coupled to COX-2 activity (169). In 
another study, Reddy et al. showed that in murine fibroblasts and macrophages, 
endotoxin stimulated the release of AA, but constitutive COX-1 could not convert this 
released AA into PGs; rather, the conversion required the expression of COX-2 (195). 
These studies suggest different functions of COX-1 and COX-2. This hypothesis is 
supported by evidence that the enzyme concentration and distribution differ. Although 
COX-1 and COX-2 are both present in endoplasmic reticulum and nuclear envelope, 
COX-2 staining was twice as concentrated in the nuclear envelope as in the endoplasmic 
reticulum (166). Recently, it was reported that COX-2-derived PGs act in the central 
nervous system to produce hyperalgesia, potentiate renin secretion in kidney, and 
modulate vascular tone and thrombosis in the cardiovascular system. (96, 186, 254, 266). 
The catalytic capacities of both COX-1 and COX-2 are under physiological 
control. AA is transformed into the prostaglandin endoperoxide PGG2 by the enzyme 
prostaglandin endoperoxide synthase (PES), the alternate chemical name for the COX 
enzyme. PES has both COX and peroxidase activities. The COX activity in both COX-1 
and COX-2 is inherently latent and its activation requires interaction with the 
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hydroperoxides. The requirement for hydroperoxide-induced activation differs between 
COX-1 and COX-2. COX-2 requires much lower levels of hydroperoxide than does 
COX-1 (138). For example, Capdevila et al. demonstrated that only COX-1 activity was 
inhibited by reduced glutathione (GSH), which decreases the availability of the 
hydroperoxide activator (32). 
The differences in the expression, intracellular localization, activation and 
function between COX-1 and COX-2 provide some possible explanations of the effects 
of estrogen on the expression of these enzymes (see below). 
 
 2.2.3.3. Prostaglandin metabolism 
The COX activity of PES transforms AA into prostaglandin endoperoxide PGG2, 
and the peroxidase activity further transforms PGG2 into endoperoxide PGH2. In 
cultured fibroblasts, immunochemical studies show that PES is present in the 
endoplasmic reticulum and the nuclear membrane, but not in the plasma membrane or 
the mitochondrial membrane (200).  
Several enzymes then further convert PGH2 into different prostaglandin 
metabolites. Thromboxane synthase (TxS) converts PGH2 into TxA2; prostacyclin 
synthase converts PGH2 into prostacyclin (PGI2); and other isomerases convert PGH2 
into the various PGs (PGD2, PGE2, PGF2α) (162, Fig. 4). PGG2, PGH2, TxA2 and PGI2 
are chemically unstable (t1/2 = 30 sec), and under physiological conditions, they are 
rapidly degraded into inactive metabolites. Other PGs (PGD2, PGE2, PGF2α), although 
more stable, are still metabolized rather quickly (t1/2  60 sec) (84, 90, 175, 209, 234). 
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Thus, prostanoids (PGs and thromboxane) are likely to be active only at the sites of their 
production, or in the immediate vicinity. 
 
2.2.3.4. Functions of prostaglandins 
2.2.3.4.1. Thromboxane   
TxA2 is the metabolite of PGH2 mainly produced from blood platelets (141). 
TxA2 spontaneously hydrolyzes to its inactive product thromboxane B2 (TxB2). TxA2 
acts on the PGH2/TxA2 receptor (TP) to induce vasoconstriction and platelet 
aggregation.  
TP is a G protein-coupled rhodopsin-type receptor with 7 transmembrane 
domains (97). TxA2 acts on its receptor in VSM to activate Gq-protein, which activates 
phospholipase C, leading to inositol 1,4,5-triphosphate (IP3) production, and subsequent 
mobilization of intracellular Ca2+, causing vasoconstriction. TxA2 receptor-mediated 
contraction of VSM also involves influx of extracellular Ca2+ via L-type and non-L-type 
calcium channels (108, 197). Since TxA2 and PGH2 share the same receptor (157, 248), 
both PGH2 and TxA2 exert similar effects via the same receptor. Even in the absent of 
TxA2, for example in the presence of TxS inhibitor, PGH2 will still activate TP and 
modulate cardiovascular function such as platelet aggregation or vasoconstriction. 
TxA2 may contribute to the pathogenesis of some cardiovascular diseases. 
Walinsky et al. showed that during the early stages of acute myocardial infarction 
(AMI), TxA2 production increased in AMI patients and in left anterior descending 
artery-occluded dogs (253). In newborn pigs exposed to chronic hypoxia for 3 days, the 
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constrictor response of pulmonary arteries to ACh was abolished by the TxS inhibitors 
dazoxiben or feregrelate, or the TP antagonist SQ-29,548, which suggests the 
involvement of TxA2 and/or PGH2 in the development of this model of pulmonary 
hypertension (69). Monocrotaline pyrrole (MCTP) causes pulmonary endothelial cell 
injury and pulmonary hypertension in rats. It was reported that MCTP treatment 
increased the release of TxB2 from isolated rat lungs, thereby suggesting the 
involvement of TxA2 in the development of pulmonary hypertension (76). Similarly, in 
the rabbit pulmonary artery, AA and methacholine both caused the contraction of the 
artery as well as the release of TxA2 and PGI2. Indomethacin (COX inhibitor), dazoxiben 
(TxS inhibitor), SQ-29,548 (TP antagonist) and removal of the endothelium all abolished 
the vasoconstriction. These findings indicate that TxA2 mediates the endothelium-
dependent contractions in rabbit pulmonary artery (30). Furthermore, in migraine 
headache patients, the plasma level of 11-dehydrothromboxane B2, a reliable indicator of 
TxA2, is significantly greater than levels in tension-type headache patients or in control 
group patients (127). Based upon studies of the relationship between TxA2 and certain 
cardiovascular diseases, TxS inhibitors and TP antagonists become potential therapies 
for these cardiovascular diseases (66, 75, 114, 198). 
 
2.2.3.4.2. Prostacyclin 
Vascular endothelial cells as well as VSM cells can convert PGH2 to PGI2 via the 
enzyme prostacyclin synthase. The endothelium has a much higher capacity (about 10-
fold) to produce PGI2 than VSM due to the higher COX content of the former cell type 
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(55, 161). PGI2 is very unstable and spontaneously degrades to its stable metabolite 6-
keto-PGF1α. The functions of PGI2 are opposite to those of TxA2. PGI2 interacts with the 
prostacyclin receptor (IP) to cause vascular relaxation and inhibit platelet aggregation by 
increasing cAMP levels in platelets and VSM cells (176). 
PGI2 plays an important role in regulating cardiovascular functions. An 
imbalance of TxA2 and PGI2 is associated with the pathogenesis of some cardiovascular 
diseases such as pulmonary hypertension and atherosclerosis (37, 76, 106, 244). Further, 
increased 24-hour urinary excretion of TxB2 and decreased 24-hour urinary excretion of 
6-keto-PGF1α are observed in postmenopausal women who have increased incidences of 
cardiovascular diseases (109). PGI2 analogues are successfully used in the treatment of 
pulmonary hypertension (80, 183). 
 
2.2.3.4.3. Other prostaglandins 
Prostaglandin D2 has a lower potency than PGI2 to inhibit platelet aggregation, 
increase cAMP level and cause peripheral vasodilation. Another difference from PGI2 is 
that PGD2 can also cause pulmonary vasoconstriction and bronchoconstriction (42, 257).  
Prostaglandin E2 has diverse effects. There are at least four G-protein-linked 
subtypes of the prostaglandin E2 receptor (EP): EP1, EP2, EP3, and EP4. EP3 and EP4 
receptors are widely distributed throughout the body, whereas the EP1 receptor is 
expressed mainly in kidney, lung and stomach, and is the least abundant among the EP 
receptors (26, 175). EP2 and EP4 receptors increase cAMP level in VSM cells via Gs 
protein and cause vasodilation (42). EP1 and EP3 receptors cause VSM contraction. The 
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EP1 receptor increases calcium mobilization and the EP3 receptor inhibits cAMP via Gi 
protein (42). PGE2 was also reported to antagonize VP-induced water reabsorption in the 
renal collecting duct by inhibiting VP-stimulated accumulation of cAMP (77). 
 
2.2.4. Interactions among vasoactive substances 
The maintenance of vascular homeostasis requires a balance between vasodilator 
and vasoconstrictor functions, as well between platelet aggregation and anti-aggregation 
systems. Thus, there must be mechanisms present to control these opposing vascular 
functions. One of the mechanisms may involve the interactions among the vasoactive 
substances themselves. For example, NO is a major vasodilator and it can also influence 
the production of other vasoactive substances. Davidge et al. used a bovine coronary 
microvessel endothelial cell line to show that NO increased the production of both PGI2 
and TxA2 by activation of COX (50). Peroxynitrite activates the COX activities of 
prostaglandin endoperoxide synthases by serving as a substrate for the enzymes' 
peroxidase activities (138). Peroxynitrite is the metabolite of NO; thus, it may link NO 
with the biosynthesis of PGs. On the other hand, Cytokine-induced iNOS expression and 
NO production were significantly augmented in cultured VSM cells obtained from TxA2 
receptor deficient mice (TP-/-) compared to wild-type VSM cells, indicating an 
inhibitory effect of endogenous TXA2 on iNOS expression (265). Conversely, several 
vasoconstrictors, such as ANG II, VP, and NE, can stimulate the release of NO (as 
discussed above).  
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The release of AA and PGs can be regulated by other vasoactive substances 
besides NO. Kato T. et al. reported that Ach stimulated the release of endothelium-
derived contracting factors in Spontaneous Hypertensive Rats (SHR) and normotensive 
Wistar-Kyoto (WKY) rats, and PGH2 was a strong candidate among the various possible 
PGs (119). Using [3H]arachidonic acid-labeled A-10 VSM cells, Lehman JJ et al. 
showed that VP activated the release of AA via a calcium-independent phospholipase A2 
pathway (144). In rat-1 fibroblasts, phenylephrine acted on the α-adrenergic receptor to 
stimulate the release of AA via activation of phospholipase D (204).  In cultured rat 
VSM cells, Ohnaka K. et al. showed that ANG II increased COX-2 mRNA and protein 
expression and stimulated PGE2 production through the mitogen-activated protein kinase 
(MAPK)-mediated signaling pathway (178). Thus, some cardiovascular diseases that 
involve elevations in ANG II, VP or other agents, may also involve enhanced release of 
PGs. 
 
2.3. Sexual dimorphism in vascular function 
Many studies have described marked differences between male and female 
cardiovascular systems. First, as described above, the incidences of many cardiovascular 
diseases differ between men and women (25, 73, 194). Similar sexual dimorphism even 
exists under normal conditions. For example, some studies using 24-hour ambulatory 
blood pressure monitoring have shown that in normotensive 20-79 year old people, men 
had higher blood pressure than age-matched women until the age of 70 to 79 (125, 261).  
Comparison of 100 hypertensive men and 100 age-matched hypertensive women 
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revealed that women had higher resting heart rate, cardiac index, and pulse pressure and 
lower total peripheral resistance than men with the same level of arterial pressure (158). 
Second, the regulation of blood pressure differs between the sexes. The 
baroreflex, which reflects the minute-to-minute autonomic control of cardiovascular 
system, exhibits sex differences in function. Peckerman A. et al. showed that among 
normotensive subjects, men had a greater baroreceptor reflex sensitivity than women. In 
hypertensive subjects, baroreceptor reflex sensitivity was reduced in men, but not in 
women (188). Thus, men can respond to changes in blood pressure more quickly and 
accurately than can women under normal conditions, but during the development of 
hypertension, this mechanism is somehow altered in men, but less so in women.  
The production of endothelium-derived vasoactive factors is also different. The 
basal release of NO from rabbit aortic rings is greater in female than in male (91). 
Similarly, in Wistar rats, basal and ACh-evoked release of NO is also greater in female 
than in male (121). Central administration of NE and ANG II stimulates greater release 
of VP in female than in male rats (231, 232). The plasma pool of AA is 75 percent 
higher in men than in women, but the turnover rate of AA, calculated per kg body 
weight, is significantly higher in women (89). Basal release of both PGE2 and TxB2 from 
peritoneal macrophages are similar in adult male and female Fisher 344 rats, but 
zymosan and calcium ionophore A23187, which are involved in the immune response, 
stimulated more PGE2 and TxB2 release in male rats (58).  
 Third, vascular reactivity to vasoactive agents differs between the sexes, and the 
differences are species-, vasculature- and agonist-specific. In the isolated, perfused rat 
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lung, the pressor response to the TxA2 mimic U-46619, but not to ANG II, is greater in 
female than in male rats (65). In contrast, in the dog, coronary and renal vascular 
responses to U-46619 are greater in male than in female (117). Maximal contractile 
responses to KCl and the calcium channel agonist Bay K 8644 are similar in male and 
female rat aorta; however, the sensitivity to both KCl and Bay K 8644 are greater in the 
male (63). Contractile responses of the female rat aorta to VP were more than twice that 
of the male aorta, while the responses to PE in the female aorta were half that of the 
male aorta (224). Altura BM. studied the mesenteric artery in situ in intact male, female 
and male rats pretreated with a single dose of 17β-estradiol (2 or 10 mug/100 g s.c.) to 
test the influence of sex on the vascular responses to vasoactive hormones. They 
concluded that the dose-response curves for the constrictor catecholamines (epinephrine 
and NE) and neurohypophyseal hormones (vasopressin, oxytocin, vasotocin) were 
shifted leftward significantly in female rats compared to male. Pretreatment of male rats 
with estrogen resulted in an enhancement of the constrictor actions of the 
catecholamines and the neurohypophyseal hormones (5). In Spontaneously Hypertensive 
Rat (SHR) aorta, ACh-induced endothelium-dependent relaxation is more pronounced in 
female, but ACh only evokes endothelium-dependent contraction in quiescent thoracic 
aortic rings from male but not from female SHR (121). These sex differences in vascular 
reactivity may result from differences in agonist-induced downstream cellular events in 
female and male, from sex differences in agonist-stimulated release of endothelium-
derived vasoactive substances, or from male-female differences in expression and 
sensitivity of receptors to those agonists. For example, Cunard CM. et al. showed that 
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the maximal response of rat pulmonary artery to U-46619 and NE were not different 
between female and male, but after removal of the endothelium, the response to U-46619 
was decreased only in female and the response to NE was not affected by denuding the 
endothelium (48). This experiment suggests that U-46619 but not NE may stimulate the 
release of an endothelium-derived contractile factor in the female rat pulmonary artery. 
The sexual dimorphism observed in cardiovascular system functions strongly 
suggests that sex steroid hormones play an important role in the regulation of the 
cardiovascular system.  
 
2.4. Effects of estrogen on the cardiovascular system 
2.4.1. Metabolism of estrogen 
The female sex steroid hormones include estrogen (E2: estradiol and E1: estrone) 
and progesterone. They are mainly produced in the ovary from cholesterol and, 
particularly in postmenopausal women, from conversion of androgen precursors in 
peripheral tissues (especially adipose tissue). The biosynthesis of estrogen is shown in 
Fig. 5. 
There are multiple pathways for estrogen metabolism in the liver as well as 
estrogen-responsive target organs (Fig. 6). These include oxidative metabolism by 
NADPH-dependent cytochrome P450 enzymes (hydroxylations) (153), and conjugative 
metabolism by glucuronidation, sulfation (93, 270) and O-methylation (11). Metabolites 
of estrogen are often inactive, but some do possess biological activity. The metabolites 
exert their biological effects either by the classical cytoplasmic estrogen receptors or by  
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Fig. 5. Biosynthesis of steroids in the ovary. 1, Cholesterol side chain cleavage enzyme 
complex; 2, 17α-hydroxylase; 3, aromatase. 
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Fig. 6. Multiple pathways for estrogen metabolism. ST, sulfotransferase; GT, 
glucuronosyltransferase; COMT, Catechol-O-Methyltransferase; 17β-HSD, 17 β-
hydroxysteroid dehydrogenase. EAT, estradiol acyltransferase. 
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different membrane-bound receptors (270). Estradiol and estrone are both converted into 
the metabolite estriol in the liver. Estrogenic hormones are eliminated from the body by 
the kidney as water-soluble metabolites, such as glucuronides and sulfate, or as lipid-
soluble metabolites, such as estriol, via urinary excretion. 
 
2.4.2. Estrogen receptors 
The estrogen receptor (ER) belongs to the nuclear receptor superfamily. In 1966, 
Toft and Gorski identified a protein in the rat uterus that specifically bound to 3H-17β-
estradiol (239). Human ER was first cloned and sequenced from MCF-7 human breast 
cancer cells (86). In 1996, Kuiper et al. cloned a novel estrogen receptor from a rat 
prostate cDNA library (135). This subtype of ER is named ERβ and the first ER is 
named ERα.  
 
 2.4.2.1. The structure of ERs 
The ER contains six different functional domains (Fig. 7). Starting from the N-
terminal end is the A/B domain, which contains 185 amino acids and is the least 
conserved region of the ER. It contains a constitutive transcriptional activation function 
1 (AF-1). AF-1 is tissue- and cell-specific, hormone-independent, and is involved in 
protein-protein interactions with other transcription factors (242). C domain has 66 
amino acids, contains the DNA binding domain DBD, and is responsible for recognition 
of specific DNA sequences and DNA binding. The DBD in the ER has two zinc finger-
like structures. The first zinc finger directly interacts with the estrogen response element 
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(ERE) in the target gene promoter region, which is a specific 13-bp palindromic 
sequence in the DNA major groove, and is responsible for the recognition of this 
sequence (212, 213). The second zinc finger is involved in the formation of ER 
homodimer. The D region of ER contains the nuclear location signal and is also involved 
in protein-protein interactions (267). The E region of the ER is a complex domain that 
has several important functions, including association with heat shock proteins, ligand 
binding, dimerization, nuclear translocation, and transcriptional activation function 2 
(AF-2). AF-2 is ligand-dependent and can act independently or synergistically with AF-
1 to activate transcription. The differential activities of AF-1 and AF-2 are dependent on 
promoter- and cell- context, and may be mediated by adaptors or coactivators that are 
specific to one or the other domain. The function of the F region of the ER is unclear; it 
is not well conserved, and it may affect the agonist/antagonist effects of antiestrogens 
(164). 
 
 
Fig. 7. Structure and homology of human ERα and ERβ proteins. 
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2.4.2.2. ERβ
In 1996, Kuiper et al. cloned a novel estrogen receptor, ERβ, from a rat prostate 
cDNA library (135). Subsequently, human and mouse ERβ was cloned (167, 241). ERα 
is on human chromosome 6, whereas, ERβ is on chromosome 14 (64). ERβ is highly 
homologous to ERα (Fig. 7); however, the AF-1 region in the A/B domain and the F 
region in ERα and ERβ are different, suggesting that their hormone-independent activity 
and protein interactions may be different.  
The tissue distribution and relative levels of ERα and ERβ are different. ERα is 
expressed in most female organs including the ovaries, the reproductive tract, the 
mammary glands, the cardiovascular system and the brain. In contrast, ERβ is highly 
expressed in the ovary, but is present in lower amount in other tissues. However, it was 
reported that ERβ is the ER form that predominantly expressed in human vascular 
smooth muscle cells, especially in women (99). ERβ is also expressed in male organs and 
different areas of the central nervous system. In the mouse, ERβ is highly expressed in 
prostate and ovaries, but low levels are observed in the uterus, lung, testis, brain and 
artery (45).  
ERα and ERβ may signal in different ways depending upon the ligand and 
response element. For example, at the AP1 site, 17β-estradiol activates transcription 
with ERα, but inhibits transcription with ERβ. The antiestrogens, like tamoxifen, 
raloxifene, and ICI 164384 are potent transcriptional activators with ERβ at the AP1 site 
(184). 
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2.4.3. Mechanisms of ER-mediated long-term (genomic) action 
2.4.3.1. Hormone dependent signaling pathway 
In the absence of ligand, ER is associated with heat shock proteins (hsp90, hsp70 
and hsp56) (16, 192) and remains inactivated. Ligand binding phosphorylates several 
sites of the ER and results in a conformational change, heat shock protein disassociation, 
receptor homodimerization, and binding of the receptor with a specific region of the 
DNA (estrogen response element, ERE), which then stimulates gene transcription (Fig. 
8, pathway 1). The second pathway for ER-mediated gene transcription is dependent  
 
 
Fig. 8. Models of ER-mediated transactivation. 
 
 
 
upon the AP1 site in the promoter. In this pathway, ER binds to Fos-Jun proteins 
that bind to the AP1 enhancer motif (233) (Fig. 8, pathway 2). Some EREs only have 
half-site palindromes. In this situation, the half-site ERE motif is stabilized by selective 
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transcription factor 1 (Sp1), and ER does not interact with ERE directly, rather it 
interacts with the Sp1/ERE(1/2) complex to stimulate gene transcription (191) (Fig. 8, 
pathway 3). 
 
2.4.3.2. Hormone-independent ER-mediated transactivation 
Many studies have shown that growth factors can phosphorylate ER, specifically 
in the A/B region, via mitogen-activated protein kinase (MARK), and thus activate ER 
and induce ER-mediated gene transcription (8, 28). 
 
2.4.4. Membrane ER and short-term (non-genomic) action of estrogen 
In addition to the classic cytoplasmic ER, several studies have reported the 
existence of a plasma membrane ER (mER) (20). Although linkage to the signaling 
pathways inside cell is not well understood, many studies have shown that mER has 
multiple functions. Within a few seconds to minutes after binding with mER, estradiol 
can trigger an intracellular Ca2+ spike through a PLC-dependent mechanism involving 
store-operated Ca2+ channels (190) and stimulate a PKC pathway (140). Activation of 
mER can also stimulate rapid NO release and cGMP formation following a transient 
increase in intracellular Ca2+ level (206, 228). Very low concentrations of estrogen (pM 
~ nM) can stimulate rapid cAMP generation (9). Estrogen can also stimulate rapid 
opening of Ca2+-activated K+ channels via NO and cGMP, and both NO and K+ channel 
activation will lead to vasodilation (203). Estrogen acts upon plasma membrane ER that 
is located in membrane caveolae and directly activates eNOS and stimulates NO release 
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without changing cytosolic Ca2+ concentration (126). mER can also regulate 
transcription; for example, mER can activate fos transcription via extracellular-signal-
regulated kinase (ERK) in a human neuroblastoma cell line SK-N-SH (258).  
 
2.4.5. Effects of estrogen on the cardiovascular system – the controversy 
ERs are expressed throughout the cardiovascular system and they are present in 
both vascular endothelial cells (7, 38, 41) and VSM cells (7, 103, 173, 181, 196). 
Treatment of the female baboon and the male rat with 17β-estradiol causes reductions in 
ER number in cytoplasmic preparations and enhancement of ER in nuclear preparations 
from both aorta and myocardium of both species (146, 147). The ability of 17β-estradiol 
to alter localization of cardiovascular estrogen receptors between cytoplasmic and 
nuclear fractions suggests that these ERs are physiologically functional and indicates 
that estrogen may directly regulate cardiovascular cell function. Estrogen exerts long-
term, genomic effects on the vascular system by altering expression of genes that 
regulate synthesis of proteins that influence vascular tone and homeostasis. Estrogen 
also exerts non-genomic effects that rapidly induce vasodilation. The effects of estrogen 
on the cardiovascular system appear to involve both protective and deleterious effects. 
 
2.4.5.1. The protective effects of estrogen 
Epidemiological studies reveal that prior to menopause, the occurrence of some 
cardiovascular diseases is significantly lower in women than in men, but after 
menopause, the incidences of cardiovascular diseases in women increases to levels 
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similar to those in men. These data suggest that female gonadal steroid hormones have 
protective effects on the cardiovascular system. Many experiments have investigated 
these effects of estrogen on the cardiovascular system and the underlying mechanisms, 
and most have reported that estrogen does exert protective effects on the cardiovascular 
system (Fig. 9). 
 
Vasodilation
Nitric oxide
Atherosclerosis
Vascular injury
Endothelial cell growth
Smooth muscle cell growth
Vascular smooth
muscle cells
 
Fig. 9. Direct effects of estrogen on blood vessels. 
 
 
 
2.4.5.1.1. Estrogen and anti-atherosclerosis 
Estrogen prevents the development of atherosclerosis through its effects on 
serum lipid metabolism, coagulation, and fibrinolysis proteins. Oral and transdermally 
administered estrogen-progestin combinations reduce serum total and LDL cholesterol 
and triglycerides in postmenopausal women (260). In postmenopausal women 
undergoing diagnostic coronary angiography, estrogen treatment significantly increases 
mean high-density lipoprotein (HDL) cholesterol level and decreases mean total/HDL 
cholesterol ratio, compared to control women who did not receive estrogen therapy 
(100). 
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The effects of estrogen on coagulation and fibrinolytic cascades are shown in 
Fig. 10. Estrogen has both prothrombotic and antithrombotic effects. It can increase 
factors VII and factor Va, and decrease antithrombin III and protein C, which favor the 
formation of thrombosis; conversely, it also increases plasminogen, decreases fibrinogen 
and plasminogen activator inhibitor-1, which prevents the formation of thrombosis. The 
net effect is unclear. Some studies indicate that estrogen increases the release of TxA2 to 
cause platelet aggregation (262). The prothrombotic action and the effect to increase 
TxA2 formation may be responsible for the increased risk for venous thrombosis that 
occurs with the use of oral contraceptives and postmenopausal hormone replacement 
therapy (49).  
 
 
2.4.5.1.2. Estrogen and vascular injury 
The protective effect of estrogen against vascular injury appears to be mediated 
by its proliferative effect on endothelial cells and antiproliferative effect on VSM. 
17β-estradiol enhances human umbilical vein endothelial cell proliferation, both 
in vitro and in vivo (165). Estrogen also inhibits apoptosis in human umbilical vein 
endothelial cells in a dose-dependent, receptor-mediated manner (222). The proliferative 
effect of estrogen on the endothelium may be due in part to its effect to increase 
expression of vascular endothelial growth factor (VEGF) (133). Estrogen inhibits the 
migration and proliferation of VSM cells (21, 130). 17β-Estradiol inhibits uptake of 
[3H]thymidine by female rats, an index of cell proliferation; furthermore, preincubation 
with tamoxifen, an ER antagonist, abolishes this inhibitory effect of estradiol, which 
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Fig. 10. Effects of estrogen on the coagulation and fibrinolytic cascades. Up or down 
arrows indicate effects of estrogen. The pro-thrombotic effects of estrogen are boxed; the 
anti-thrombotic effects are underlined. (-) indicates inhibitory action. ATIII, 
antithrombin III; PAI-1, plasminogen activator inhibitor-1; tPA, tissue plasminogen 
activator.  
 
 
 
suggests that estrogen-induced inhibition of proliferation of rat carotid artery segments is 
mediated through activation of estrogen receptors (246). After balloon injury of the rat 
aorta, ERα mRNA was not changed in the male, but ERβ mRNA increased in both 
endothelium and luminal VSM cells (148). These data suggest that ERβ mediates the 
protective effects of estrogen on vascular injury.  
 
2.4.5.1.3. Estrogen and vascular reactivity 
NO is probably the most important local vasodilator. Estrogen can induce the 
release of NO, and thereby regulate vascular tone. Treatment of guinea pigs with 
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estradiol increases mRNA levels for both eNOS and nNOS in skeletal muscle 
vasculature (259). Exposure of cultured human aortic endothelial cells to 17β-estradiol 
enhances Ca2+-dependent NO release and increases NOS protein production (98). 
Further, 17β-estradiol attenuates PE-induced vasoconstriction of the endothelium-
denuded rat aorta through induction of iNOS in non-endothelial cells (22). In addition to 
its genomic effects on NOS gene expression, estrogen can also induce a rapid release of 
NO, either by activating eNOS (126) or by transiently increasing intracellular Ca2+ 
concentration (98). EM-652 (acolbifene), a fourth-generation selective ER modulator 
(SERM), not only increases eNOS protein levels during prolonged treatments, but also 
triggers NO release by human umbilical vein endothelial cells through nongenomic 
mechanisms, rapidly activating eNOS via an ER-dependent sequential activation of 
MAPKs and PI3K/Akt pathways (218). 
In the female rabbit, 17β-estradiol treatment induces relaxation of both the intact 
aorta and the coronary arteries in the perfused heart, coincident with NO formation. 
However, after removal of the endothelium, 17β-estradiol also causes direct relaxation 
of aortic and coronary smooth muscle, independent of NO formation (151). The direct 
effect of estrogen on VSM cells appears to occur via inhibition of Ca2+ entry from L-
type Ca2+ channels (43). Using the whole-cell voltage clamp technique, Nakajima T. et 
al. showed that estrogen might play a role in regulating vascular tone by selectively 
inhibiting voltage-dependent L-type Ca2+ currents in cultured rat thoracic aortic smooth 
muscle cell lines (A7r5)  (172). 
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Estrogen also stimulates the release of vasodilator prostaglandins. For example, 
estrogen increases the release of 6-Keto-PGF1α by aortic rings obtained from male 
Sprague-Dawley rats, whereas, testosterone does not. Interestingly, western blots 
revealed that preincubation of male rat aorta with estrogen decreases COX-1 and 
prostacyclin synthase protein production (171). This study suggests that estrogen can 
stimulate the release of PGI2 from male rat aortic rings through a mechanism not 
involving COX-1 or prostacyclin synthase. 
Estrogen also has effects on the renin-angiotensin system (RAS). Long-term 
treatment with estrogen decreases angiotensin-converting enzyme (193) and down-
regulates both AT1 receptor mRNA expression and receptor density in ovariectomized 
female rat aorta (177); however, opposite effects of estrogen on the RAS were also 
reported. For example, oral estrogen replacement theraphy increases angiotensinogen 
levels (211). Similarly, long-term treatment with Premarin (conjugated equine estrogens) 
significantly increased circulating renin and ANG I levels in OvX monkeys (27). The 
overall effect of estrogen on the RAS is unclear and is under continued examination. 
 
2.4.5.2. The deleterious effects of estrogen  
Although estrogen appears to exert protective effects on the cardiovascular 
system, hormone replacement therapy (HRT) does not produce significant beneficial 
effects in postmenopausal women (94, 95, 105). Some studies have even shown an 
increased risk for cardiovascular events in the first year, including venous thrombosis. 
These observations may be explained by the older age and established coronary heart 
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disease of the participants, the combined use of estrogen with an androgenic progestin 
(medroxyprogesterone), or by the possibility that estrogen may also have deleterious 
effects on the cardiovascular system.  
Several studies have shown that estrogen increases contractile responses to 
vasoconstrictor agonists. For example, Rorie et al. showed that estrogen (100 µg/day for 
4 days) increased vascular reactivity of isolated rabbit saphenous veins to NE, as well as 
methoxamine and PE (202). Similarly, contractile responses of rat thoracic aorta to VP 
are three-fold greater in female than in male, and indomethacin significantly attenuates 
the contractile responses in female but not in male aorta (70, 224). This study suggests 
that ovarian steroid hormones may enhance aortic contractile responses of the female 
aorta to VP through COX products of AA. Similarly, treatment of ovariectomized 
rabbits with 17β-estradiol enhances the contractile responses of endothelium-intact, but 
not -denuded, aortic rings to NE. Likewise, indomethacin inhibits contractions to NE in 
endothelium-intact aortic rings from estrogen-treated rabbits (159). These results suggest 
that chronic treatment with estrogen can enhance arterial reactivity to NE through an 
endothelium-dependent mechanism that may involve COX metabolites of AA.  
Studies on the effects of estrogen on the vasculature not only demonstrate 
increased reactivity to VP and NE, but also suggest that the release of and response to 
locally-produced constrictor prostanoids are enhanced in the systemic vasculature. For 
example, Witter et al. showed that estrogen increased the release of TxA2 from cultured 
umbilical cord endothelial cells (262). In the isolated, perfused rat lung, pressor 
responses to TxA2 mimic U-46619 are greater in female than in male rats, and estrogen 
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enhances the responses to U-46619 (65). Further, indomethacin attenuated contractile 
response of female rat aorta to VP, while ovariectomy attenuated contractile response to 
VP but also abolished the attenuating effects of indomethacin (70). 
The increased reactivity of the female vasculature to constrictor prostanoids may 
result from the increased expression and/or activity of enzymes such as COX and/or TxS 
that mediate formation of these local vasoconstrictors, and/or from the increased 
expression of the TP. For example, indomethacin attenuated maximal responses to VP in 
female but not male rat aortas, and SQ-29,548 (a TP antagonist) had a virtually identical 
effect as indomethacin in the female rat aorta (70). Further, indomethacin, the COX-2-
selective inhibitor nimesulide, and SQ-29,548, all significantly reduced maximal 
contractions of the endothelium-denuded rat aorta to the α2-adrenoceptor agonist 
clonidine (partial agonist relative to phenylephrine), compared to control (44). The 
controversial observations summarized above emphasize the need to further elucidate 
the effects of estrogen on vascular function and the underlying mechanisms.  
 
2.4.6. Phytoestrogens 
Phytoestrogen is a general term used to define plant-derived, estrogen-like 
molecules that include the isoflavones (genistein, daidzein), coumestans, and lignans. 
Beans and legumes are abundant sources of isoflavones, and lignans are widely found in 
cereals, fruits and vegetables (170). In humans, phytoestrogens are converted in the 
gastrointestinal tract to heterocyclic phenols that are structurally similar to estrogen (Fig. 
11). 
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Fig. 11. Comparison of the molecular structures of 17β-estradiol and phytoestrogen 
(genistein and daidzein). 
 
 
 
Phytoestrogens appear to interact selectively with ERβ over ERα, although they 
have a relatively low affinity for both receptors. Compared to estradiol, the binding 
affinity of genistein for ERα is 4%, and for ERβ is 87%; similarly, the binding affinity of 
daiazein for ERα is 0.1%, and for ERβ is 0.5% (135). The biological activities of 
phytoestrogens have been determined mainly in animal studies. Phytoestrogens have 
both estrogenic and antiestrogenic effects, depending upon the specific tissue and the 
concentrations of circulating endogenous estrogens. For example, in the human ER-
positive MCF-7 breast cancer cell line, genistein stimulates cell growth at low 
concentrations [10-5–10-8 M]; but at higher concentration [10-4–10-5 M], it exerts 
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antiestrogenic effects and inhibits cell growth (256). Phytoestrogens also exert estrogenic 
effects on lipid metabolism (237) and inhibit growth of VSM cells (59) that may 
contribute to their cardiovascular protective effects observed in Asian countries and in 
vegetarians (2, 40). The effects of phytoestrogens on vascular reactivity are unclear. A 
study on rhesus monkeys with pre-existing diet-induced atherosclerosis showed that 
coronary arteries from male constricted in response to Ach, and that arteries from female 
in the low-isoflavone group constricted in response to ACh, whereas arteries from 
female in the high-isoflavone group dilated. Intravenous administration of genistein 
caused dilation in low-isoflavone female that previously exhibited vasoconstrictor 
response to ACh. It was concluded that dietary soy isoflavones enhanced the dilator 
responses to ACh in atherosclerotic arteries in female monkeys (101). The effects of 
phytoestrogens on the vascular system still remain uncertain, and need to be elucidated 
in much further detail. 
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CHAPTER III  
EXPERIMENTAL DESIGN AND METHODS 
 
 3.1. Major objectives and central hypothesis 
Previous studies reveal that male-female differences exist in normal vascular 
function and in the occurrence of some human vascular diseases. Estrogen may enhance 
the constrictor prostanoid pathway and/or expression of TP to increase vascular tone, 
and thereby, may contribute to sexual dimorphism in vascular function and vascular 
disease. Therefore, the major objectives of this doctoral dissertation are: 1) To determine 
male-female differences in constrictor prostanoid function and vascular contraction in 
the rat aorta; and 2) To elucidate the role of estrogen in the regulation of constrictor 
prostanoid function in the rat aorta.  
The central hypothesis to be tested is that: estrogen potentiates agonist-induced 
vascular contraction of the female rat aorta by upregulating the production of constrictor 
prostanoids (TxA2 and/or PGH2) and/or TP expression. 
This hypothesis will be tested by addressing the following specific aims: 
1) To determine male-female differences in constrictor prostanoid function and 
vascular contraction in the rat aorta in vitro, and the role of estrogen in the 
regulation of these mechanisms. 
2) To determine male-female differences in TxA2 and PGI2 release by the rat 
aorta in vitro and the role of estrogen in the regulation of the TxA2 and PGI2 
biosynthesis pathway. 
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3) To determine the molecular mechanism(s) by which estrogen upregulates 
constrictor prostanoid function in the rat aorta. 
 
3.2. Materials and methods 
3.2.1. Animal/tissue preparations  
 3.2.1.1. Animals  
Age-matched (14-18 weeks old) female and male Sprague-Dawley rats (Harlan 
Labs. Inc.) were used in all studies. The rats were housed in vivarium facilities at the 
College of Veterinary Medicine (Laboratory Animal Resources and Research facility; 
LARR) with controlled temperature (22-24 °C), relative humidity (approx. 50%) and 
lighting cycle (12:12 L/D). The animals were segregated by sex and housed in pairs in 
standard plastic laboratory rat cages. Tap water and either standard laboratory chow 
(22% protein) or a phytoestrogen-free diet (soy and/or alfalfa were replaced with casein 
as the major source of protein) (7% Corn Oil Diet; Harlan, Inc.) was provided ad libitum 
according to the experiments. 
 
3.2.1.2. Animal treatment regimens 
Animals were randomly separated into 4 experimental groups: male, intact (InT)-
female, ovariectomized (OvX)-female, and OvX+estrogen-replaced (OvX+Est)-female. 
The estrous cycle of the InT-female rat was ignored since previous studies have shown 
that neither the contractile responses of the female rat aorta to VP or PE, nor stimulation 
of prostaglandin production by catechol estrogens differ with phase of the estrous cycle 
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(124, 224).  For each group, sample sizes of 3-9 rats were used to account for 
experimental loss and known levels of statistical variability in vascular experiments and 
molecular studies in vitro. Ovariectomy surgery was performed when female rats were 
4-5 weeks old, using standard methods, and estrogen was replaced at the age of 8-9 
weeks for 21-28 days by subcutaneous implant of 2-0.05 mg, 60-day-release pellets of 
17β-estradiol (Innovative Research, Inc.; Sarasota, FL). Previous studies have shown 
that this dose produces physiological concentrations of 17β-estradiol in the plasma of 
female rats (250).  
 
3.2.1.3. Preparation of isolated thoracic aorta  
After sacrifice by rapid decapitation, the thoracic aorta was gently removed to 
avoid stretching the vascular smooth muscle or damaging the endothelium. The aorta 
was then placed in chilled Krebs-Henseleit-bicarbonate solution (KHB) (4° C) and kept 
gassed with 95% O2/5% CO2. The composition of the KHB included (in mM) 4.74 KCl, 
2.5 CaCl2, 25.0 NaHCO3, 118.0 NaCl, 1.18 MgSO4, 1.18 KH2PO4, and 10.0 Glucose. 
All adipose and connective tissue were removed and the mid-thoracic region was 
sectioned into rings (3 mm length). Aortas were studied either with the endothelium 
intact (Endo+) or with the endothelium denuded (Endo-) by gently passing a frayed 
nylon string through the lumen (225). The rings were then carefully mounted on two 25-
gauge stainless steel wires. The upper one was attached to a force-displacement 
transducer (Grass FT-03D), and the lower one was attached to a stationary stainless steel 
rod and micrometer, which allowed adjustment of the passive tension of the ring (224). 
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The transducer was connected to a polygraph (Gould 2600S) for a continuous record of 
the isometric tension produced by the aortic ring. 
 
3.2.2. General experiment methods 
3.2.2.1. Isometric tension studies 
Immediately after mounting, aortic rings were immersed in water-jacketed organ 
baths filled with 15.0 ml warmed (37 °C) KHB solution continuously gassed with 95% 
O2/5% CO2. Passive tension was then gradually (over a 30 minute period) increased to 
2.50 g, which is optimal for both male and female rat aortas, as demonstrated in previous 
studies (224, 225). The tissues were allowed to equilibrate for 90 minutes, and the KHB 
was replaced with warmed, freshly gassed KHB solution every 20 minutes, and passive 
tension was adjusted to maintain 2.50 g. After equilibration, a near-maximal 
concentration of PE (1x10-6 M, final concentration) was added to the baths to stabilize 
the aortas; after the contractions attained a stable plateau tension, the endothelium-
dependent vasodilator acetylcholine (ACh, 1x10-7 M) was added to the baths to test the 
functional integrity of the endothelium. After the maximal relaxation was attained, the 
baths were changed twice and the tissues were allowed to re-equilibrate for 30-45 
minutes. A second stabilizing contraction and relaxation to PE and ACh were then 
obtained as described above. After a second re-equilibration period, either U-46619 (1 x 
10-11 - 3 x 10-6 M) or VP (1x10-11 - 1x10-6 M) was added to the baths in a cumulative 
manner to obtain a concentration-response curve for each ring. At each concentration, a 
stable plateau tension was attained before increasing the concentration of the agonist. 
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3.2.2.2. Basal and agonist-induced release of TxB2 and 6-keto-PGF1α  
Paired, adjacent aortic rings (3 mm length) obtained from each of the four 
experimental animal groups, were cleaned of all connective tissue and fat, and were then 
placed into chilled (4 °C), KHB solution, gassed with 95% O2/5% CO2, and allowed to 
stabilize for at least 30 minutes. The paired rings were then transferred into 12x75 mm 
plastic culture tubes containing 2 ml chilled KHB, and allowed to gradually warm to 37 
°C. The tissues were then pre-incubated at 37 °C and gassed continuously for 30 
minutes, and the KHB solution was then carefully aspirated. Immediately thereafter, 1.0 
ml of either KHB alone (basal) or KHB with low-dose (10-8 M) VP or high-dose (10-6 M) 
VP was added to the tubes and the tissues were incubated for 45 minutes at 37 °C and 
gassed constantly with 95% O2/5% CO2. After incubation, the KHB was aspirated and 
stored at –70 °C until radioimmunoassay (RIA) of TxB2 and 6-keto-PGF1α. For some 
experiments, the aortas were pre-incubated in the presence of Indo (10 µM), NS-398 (10 
µM), or vehicle-control. 
Concentrations of TxA2 and PGI2 in the incubation media were measured in each 
sample using specific RIA for their stable metabolites TxB2 and 6-keto-prostaglandin F1α 
(6-Keto-PGF1α), respectively. Prostanoid standards (0.975-1,000 pg for TxB2 and 1.95-
1,000 pg for 6-Keto-PGF1α) or unknown samples were incubated with [3H]TxB2 or [3H]-
6-keto-PGF1α and with the appropriate prostanoid antiserum overnight for 16-20 hr at 4 
°C. The charcoal-dextran method was used to separate bound and free fractions of 
[3H]TxB2 or [3H]-6-keto-PGF1α . Bound radioactivity was counted by liquid scintillation 
spectroscopy.  The limit of detection of the RIAs was 1.95 pg/tube for TxB2 and 3.90 
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pg/tube for 6-Keto-PGF1α; the cross-reactivity of the antiserum to other prostanoids was 
<0.1%, and the intra-assay and interassay coefficients of variation were 5.0% and 7.6% 
respectively (227). 
 
 3.2.2.3. Immunohistochemistry of COX-1, COX-2 and TxS 
Freshly isolated thoracic aortas were cannulated with a 16 ga. needle and gently 
flushed with 10% neutral buffered formalin to remove blood and air from the lumen. The 
open ends of aortas were then ligated with 4-0 silk suture and the whole aortas were 
immersed in formalin and fixed under pressure (80 mmHg) for 24 hours. After fixation, 
the aortas were dehydrated with graded ethanol, embedded in paraffin, and cut into 4 µm 
thick sections. After cleaning with xylenes and rehydration with graded ethanol, the 
antigens (COX-1, COX-2, or TxS) were retrieved using the microwave oven heating 
method. Primary antibodies against TxS, COX-1 or COX-2 (Cayman Chemical, Ann 
Arbor, Michigan) were then applied, and binding was detected using a biotinylated 
secondary antibody (Cayman Chemical; Ann Arbor, Michigan) in combination with the 
avidin-biotin-horseradish peroxidase method and 3,3’-diaminobenzidine (DAB, Vector 
Laboratories, Inc., Burlingame, CA) as a chromagen. An adjacent section was used as a 
negative control, and was treated only with secondary antibody. Hematoxylin was used 
as a counterstain (30, 88).  
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 3.2.2.4. Reverse transcription-polymerase chain reaction (RT-PCR) for COX-1, 
COX-2, TxS and TP  
Freshly isolated aortas were opened longitudinally and the endothelial cells were 
gently removed with a cotton swab that was then placed into 1.0 ml of Trizol reagent 
kept on ice. The remaining aorta was then scrubbed with another cotton swab to remove 
any remaining endothelial tissue and the resulting VSM was then placed into 1.0 ml of 
Trizol reagent kept on ice.  Freshly isolated endothelium and VSM were then 
homogenized in the 1.0 ml Trizol reagent and the RNA was extracted in 200 µl 
chloroform, 5 µl (25 µg/ml) glycogen (Ambion), 50 µl Na acetate (5 M), 500 µl 
isopropyl alcohol, 1 ml 75% ethanol and centrifuged at 4 °C, according to the 
manufacturer’s instructions. The extracted RNA was quantified by uv absorbance at 260 
nm and stored at –80 °C. Equal amounts (0.2 µg) of extracted RNA from each sample 
were subjected to reverse transcription by reverse transcriptase (Thermoscript RT-PCR 
system, GibCoBrl, Life Technologies, Grand Island, NY), using 1 µl specific antisense 
primers (Sigma-Aldrich, Genosys) in a PCR buffer (4 µl 5x buffer, 2 µl 10 mM dNTP, 1 
µl 0.1 M DTT, 1 µl RnaseOut, 1 µl Thermoscript RT) in a 20 µl total volume. The RT 
reaction was performed according to the manufacturer’s instructions. 2 µl or 5 µl cDNA, 
according to the gene expression, was then amplified in a total volume of 50 µl 
containing 1 µl 5’ specific primer, 1 µl 3’ specific primer, 1 µl Taq polymerase (Expand 
High Fidelity, Roche Molecular Biochemical, Indianapolis, IN), 5 µl 10x PCR buffer 
without MgCL2, 2 µl 10 mM dNTP, and 3 µl MgCl2. After an initial 4-min denaturation 
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step at 94 °C, the TxS cDNA was amplified for 35 cycles, and the primers were annealed 
at 54 °C. COX-1 and COX-2 cDNA were amplified for 30 cycles and the primers were 
annealed at 55° C. TP cDNA was amplified for 35 cycles and the primers were annealed 
at 55 °C. Each cycle consisted of 30s denaturation at 94 °C, 30s annealing at the specific 
temperature (except primers for TxS, which were annealed for 60s because of the longer 
length), and extension at 72 °C for 30s, followed by 7 min final extension at 72 °C.  The 
RT-PCR product was separated by gel electrophoresis on 1.8% agarose gel, visualized 
with ethidium bromide staining using Gel Doc 1000 system (Bio-Rad laboratories, 
Hercules, CA, USA), and quantified by densitometry (Multi-analyst + /Macintosh 
software, Bio-Rad laboratories). The PCR fragments were identified by size using 
standard DNA (φX174RF DNA/Hae III Fragments, Life technologies). The results were 
expressed as the light intensity ratio of the ‘specific’ mRNA and the housekeeping gene 
GAPDH (glyceraldehydes-3-phosphate dehydrogenase) amplified in the same tissues. 
The negative control was performed under the same conditions without Taq polymerase. 
The specific primers used are shown in Table 2. (19, 92). 
 
3.2.2.5. Drugs 
 The following drugs were used: 17β-estradiol (0.05 mg 60-day-release pellets; 
Innovative Research of America; Sarasota, FL), U-46619 (15-hydroxy-11, 9-
epoxymethanoprosta-5Z, 13E-enoic acid), NS-398 (N-[2-cyclohexyloxy-4-nitrophenyl]-
methanesulfonamide) and Niflumic Acid (Cayman Chemical; Ann Arbor, Michigan), 
arginine vasopressin (VP, Bachem Inc., Torrance, CA), phenylephrine hydrochloride  
50  
Table 2. Specific primers (sense and antisense) for COX-1, COX-2, TxS, TP and 
GAPDH were used for RT-PCR. 
 
Gene 
 
 
Oligonucleotide Primers 
 
 
Size of 
PCR Product 
 
Reference 
 
 
COX-1 Sense:         
5’CTCACAGTGCGGTCCAAC3’ 
Antisense:  
5’CCAGCACCTGGTACTTAAG3’ 
424bp Bernard N, 2000; 
Kawaguchi H, 
1994. 
COX-2 Sense:         
5’GAAATGGCTGCAGAGTTG3’ 
Antisense: 
5’GGAATTCTCATCTAGTCTGGAGAGTTG3’ 
356bp Bernard N, 2000;  
Jensen BL, 1997. 
TxS Sense:         
5’TCCAGAGGTGTTACTGCTGT3’ 
Antisense: 
5’GAAGCATGACAAACATTTATTC3’ 
1,187bp Bernard N, 2000; 
Tone Y, 1994. 
TP Sense:         
5’TGCTGCAGACGCTACCTGTC3’ 
Antisense:  
5’GATTGGCACCGTCCTTCAGG3’ 
244bp Nanji AA, 1997. 
GAPDH Sense:        
5’GTGAAGGTCGTGTCAACGGATTT3’ 
Antisense: 
5’CACAGTCTTCTGAGTGGCAGTGAT3’ 
558bp Bernard N, 2000; 
Hughes AK, 1995. 
 
 
 
 
(PE), acetylcholine (ACh) and indomethacin (Indo, Sigma Chemical; St. Louis, MO), 
Dazoxiben HCl (DAZ, Pfizer Central Research; Sandwich, England), DAB (Vector 
laboratories, Inc.; Burlingame, CA), and Trizol reagent (Life Technologies; Rockville, 
MD, USA). Stock solutions of these drugs were prepared fresh daily except for VP 
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(which was diluted daily from aliquots of 1 x 10 –3 M stock solution stored at –70 °C) 
and NS-398 (which was diluted daily with DMSO from 1 mg/ml stock solution stored at 
–20 °C). 
 
3.2.2.6. Data analysis  
All data are expressed as means ± SE; n indicates the number of animals studied. 
Statistical analysis of the data was performed using one-way or two-way ANOVA to 
detect differences among the means of the experimental groups. If significant differences 
were detected by ANOVA, pair-wise comparisons between means of the experimental 
groups were made using a Student’s t test. A P value less than 0.05 is considered 
significantly different. 
a) For vascular reactivity experiments, contractile responses to U-46619 or VP 
were normalized by dry weight of the aortic rings and were expressed as milligram 
tension per milligram ring weight (wt). The EC50, defined as the effective concentration 
of VP or U-46619 causing 50% of the maximal contraction, was calculated from the 
individual concentration-response curve of each aortic ring.  The EC50 is reported as the 
mean ± SE for the particular experimental group.  
b) For TxA2 and PGI2 release experiments, basal release reflected the steady-
state release of the prostanoids into the incubation medium (KHB) during the 45 minute 
incubation period, and was normalized by dry weight of aortic rings and expressed as 
pg/mg dry tissue weight/45 min. Agonist-stimulated release reflects the total agonist-
stimulated release of the prostanoids into the incubation medium in the presence of a low 
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(1 x 10 –8 M) or high (1 x 10 –6 M) concentration of VP, as used in the contractile 
function experiments. 
c) For the immunohistochemistry experiments, the amount of positive staining of 
each specific protein was visualized under light microscopy (10X) and was scored on a 
scale of 1 – 4 by a naïve individual blinded to the sex or treatment of the experimental 
animal. The weakest positive stain was scored as 1 and the strongest positive stain was 
scored as 4.  
d) For RT-PCR experiments, the results were expressed as the light intensity 
ratio of the specific mRNA and the housekeeping gene GAPDH mRNA obtained from 
the same tissues. 
 
3.3. Experimental design 
3.3.1. Specific aim 1: To determine male-female differences in constrictor 
prostanoid function and vascular contraction in the rat aorta in vitro, and 
the role of estrogen in the regulation of these mechanisms 
 3.3.1.1. Rationale 
Previous studies reveal that a marked sexual dimorphism exists in vascular 
reactivity of the rat aorta to VP. Maximal contractile response to VP is three-fold greater 
in the female than in the male aorta (70, 224, 225). Previous studies also established that 
VP-stimulated release of NO is much greater in the male rat aorta and is responsible for 
the attenuated responsiveness to VP. Interestingly, even in the presence of NOS 
inhibition, contractile responses of the rat aorta to VP are still significantly higher in 
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female, and the COX inhibitor indomethacin attenuates contractile responses to VP in 
the female but not male aorta (70, 225). These data suggest that constrictor products of 
COX may contribute to the enhanced vascular reactivity of the female rat aorta to VP. 
Therefore, in the present studies, the effects of COX inhibition on contractile responses 
of the female rat aorta to VP and the role of estrogen in regulating these responses to VP 
were examined. The role of estrogen in modulating constrictor prostanoid function was 
further examined by determining vascular reactivity to TxA2 in the thoracic aortas of 
male and female rats. 
 
 3.3.1.2. Specific aim 1 experiments 
Protocol 1: To determine the effects of cyclooxygenase inhibitors on 
contractile responses of female rat aorta to VP 
The effects of prostanoid pathway inhibitors on vascular reactivity to VP were 
examined by obtaining cumulative concentration-responses to VP (1 x 10-11 - 1 x 10-6 M) 
in endothelium-intact (Endo+) aortas prepared in triplicate from InT-female rats in the 
presence of the following: 1) The non-selective COX inhibitor indomethacin (Indo, 
10 µM); 2) The COX-2-selective inhibitor NS-398 (NS; 10 µM); or 3) vehicle-control 
(0.13% DMSO in KHB). Aortic rings were pretreated with inhibitors or vehicle 20 min 
before the concentration-response to VP was obtained. To examine whether the effects 
of the COX-2-selective inhibitor were agent-specific, cumulative concentration-
responses to VP in InT-female rats were also obtained in the presence of a second, 
chemically-dissimilar COX-2-selective inhibitor, niflumic acid (NA, 10 µM).  
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Protocol 2: To determine the effects of ovariectomy and estrogen 
replacement therapy on contractile responses of female rat aorta to VP  
To determine the effects of estrogen on vascular reactivity and constrictor 
prostanoid function in the female rat aorta, cumulative concentration-responses to VP 
(10-11-10-6 M) were obtained in Endo+ aortic rings prepared in triplicate from OvX-
female, and OvX+Est-female rats. Rings from each aorta were pretreated with Indo 
(10 µM), NS (10 µM), or vehicle (control). 
Protocol 3: To determine male-female differences in contractile responses to 
exogenous TxA2 and the role of the endothelium 
Male-female differences in contractile responses to TxA2 and the role of the 
endothelium were determined by obtaining cumulative concentration-responses to the 
TxA2 analog U-46619 (1 x 10-11 M - 3 x 10-6 M) in paired Endo+ and Endo- aortic rings 
obtained from male and InT-female rats. 
Protocol 4: To determine the effects of estrogen on female vascular 
reactivity to U-46619 
Cumulative concentration-responses to U-46619 (1 x 10-11 M - 3 x 10-6 M) were 
obtained in Endo+ aortic rings obtained from OvX-female and OvX+Est-female rats. 
Protocol 5: To determine the effects of dietary phytoestrogens on the 
contractile responses of the rat aorta to VP and U-46619 
The protein contents of regular rat chows are frequently enhanced by the addition 
of soybeans and alfalfa to the chow. These substances add significant amounts of 
phytoestrogen compounds to the diet. These compounds appear to exert estrogenic 
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actions at the estrogen receptor (2, 40, 59); therefore, the effects of phytoestrogens on 
vascular reactivity to VP and U-46619 were studied. 4-5 weeks old InT-female and 
OvX-female rats were fed a phytoestrogen-free diet in which casein replaced soy or 
alfalfa as the major source of dietary protein (7% corn oil diet, Harlan Tek-Lad) until 
they reach 14-15 weeks old. Aortic rings prepared from these phytoestrogen-free rats 
were used to obtain concentration-responses to VP and U-46619 in separate groups of 
female rats. 
 
3.3.2. Specific aim 2: To determine male-female differences in TxA2 and PGI2 
release by the rat aorta in vitro and the role of estrogen in the regulation of 
the TxA2 and PGI2 biosynthesis pathway 
3.3.2.1. Rationale 
TxA2 and PGI2 are both important vasoactive substances derived from the 
metabolism of AA in the vascular wall. The relative balance of their synthesis and 
release will result in a net increase or decrease in local vascular tone. Previous studies 
have established that sex differences exist in the contractile responses of the vasculature 
to VP and PE, and that male-female differences in agonist-induced TxA2 function may 
be involved in these sex differences (70, 224, 225, 226, 227). Therefore, basal and 
agonist-induced release of TxA2 and PGI2 by male and female rat aortas were assessed 
by radioimmunoassay of their stable metabolites, TxB2 and 6-keto-PGF1α respectively. 
The effects of OvX and estrogen replacement therapy on the release of TxA2 and PGI2 
by the female aorta were also determined. 
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3.3.2.2. Specific aim 2 experiments 
Protocol 1: To determine male-female differences in basal and agonist-
stimulated release of TxA2 and PGI2   
Aortic rings, prepared in triplicate from InT-female or male rats, were incubated 
in 1.0 ml of fresh KHB either alone (basal) or with low-dose (10-8 M) VP or high-dose 
(10-6 M) VP, continuously gassed (95% O2/5% CO2) for 45 minutes at 37 °C. After 
incubation, the KHB was collected and stored at –70 °C until specific RIA of TxB2 and 
6-keto-PGF1α. 
Protocol 2: To determine the effects of OvX and estrogen replacement 
therapy on the release of TxA2 and PGI2     
 Aortic rings from InT-female, OvX-female, or OvX+Est-female rats were 
prepared in triplicate to measure basal and low- or high-dose VP-stimulated release of 
TxA2 and PGI2 as described in Protocol 1.  
Protocol 3: To determine the effects of COX and TxS inhibition and 
estrogen on the release of TxA2 and PGI2
Aortic rings prepared in quadruplicate from male, InT-female, OvX-female and 
OvX+Est-female rats were pre-incubated in either KHB alone or in the presence of Indo 
(10 µM), NS (10 µM), or dazoxiben (DAZ, TxS inhibitor, 50 µM). The rings were then 
incubated (45 min, 37 °C) with KHB containing 10-6 M VP either alone, or in the 
presence of 10 µM Indo, 10 µM NS or 50 µM DAZ, respectively. After incubation, 
KHB was collected, stored, and analyzed as described in protocol 1. 
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3.3.3. Specific aim 3: To determine the molecular mechanism(s) by which estrogen 
upregulates constrictor prostanoid function in the rat aorta 
3.3.3.1. Rationale 
Previous studies suggest that estrogen may enhance constrictor prostanoid 
pathway function, and thereby, potentiate contractile responses of the female rat aorta; 
however, the underlying mechanism(s) are still unclear. Estrogen may alter the 
expression of COX and/or TxS, thereby enhancing the production of TxA2 and PGI2. 
Estrogen may also affect the expression of TP by VSM cells to enhance the contractile 
responsiveness to TxA2. Therefore, the expression of key prostanoid pathway enzyme 
messages for COX-1, COX-2 and TxS was determined by RT-PCR and the synthesis of 
the associated enzyme proteins were estimated by immunohistochemistry. Expression of 
TP message was also determined by RT-PCR. The effects of OvX and estrogen 
replacement therapy on the expression of these key prostanoid pathway enzyme mRNAs 
and their associated proteins were also examined.  
 
3.3.3.2. Specific aim 3 experiments 
Protocol 1: To determine the mRNA levels of COX-1, COX-2, and TxS by 
rat aorta and the effects of OvX and estrogen replacement therapy on their 
expression 
Isolated aortic endothelium and VSM cells from male, InT-female, OvX-female, 
and OvX+Est-female rats were prepared to detect the mRNA levels of COX-1, COX-2, 
and TxS using the method of RT-PCR. 
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Protocol 2: To determine the protein expression of COX-1, COX-2 and TxS 
enzymes and the effects of OvX and estrogen replacement therapy on their 
expression 
Aortic rings prepared from male, InT-female, OvX-female and OvX+Est-female 
rats were used for immunohistochemistry study to determine the protein expression of 
COX-1, COX-2, and TxS in aortic endothelium and VSM.  
Protocol 3: To determine the expression of TxA2 receptor (TP) mRNA by 
rat VSM cells and the effects of OvX and estrogen replacement therapy on TP 
expression 
Isolated aortic VSM from male, InT-female, OvX-female and OvX+Est-female 
rats were prepared to detect the expression of TP mRNA levels by the method of RT-
PCR. 
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CHAPTER IV 
RESULTS 
 
4.1. Specific aim 1: To determine male-female differences in constrictor prostanoid 
function and vascular contraction in the rat aorta in vitro, and the role of 
estrogen in the regulation of these mechanisms 
4.1.1. Effects of COX inhibitors on contractile responses of female rat aorta to VP 
 In the InT-female rat aorta, both the non-selective COX inhibitor Indo and the 
COX-2-selective inhibitor NS-398 significantly attenuated contractile responses to VP at  
 
 
Table 3. EC50 and corresponding maximal contractile responses to vasopressin in 
thoracic aortas of intact-, OvX-, and OvX+Est-female (F) Sprague-Dawley rats 
pretreated with indomethacin, NS-398 or vehicle-control. The OvX-female rats were fed 
with phytoestrogen-free diet. 
 
Group InT-F (n=5) 
 
OvX-F (diet) (n=6) 
 
OvX+Est-F (n=8) 
 
 EC50 
(nM) 
Maximal 
contractile force 
(mg/mg ring wt) 
EC50 
(nM) 
Maximal 
contractile force 
(mg/mg ring wt) 
EC50 
(nM) 
Maximal 
contractile force 
(mg/mg ring wt) 
 
Cont 8.0±1.2c 5,567±276g 9.2±1.5c 2,485±394ef 4.9±0.4a 5,059±194g
Indo 6.1±0.4ac 3,176±179f 7.5±0.7c 1,666±182e 5.6±0.9ab 3,643±264f
NS 10.9±1.6d 3,258±152f 9.0±1.0c 1,833±171e 7.6±0.4b 3,457±261f
 
Values are means ± SE; n, no. of animals. EC50, concentration of agonist 
producing 50% of the maximal contractile response; Cont, vehicle-control; Indo, 
indomethacin (10 µm); NS, NS-398 (10 µm). a-g Within columns and rows for each 
group (intact vs. OvX vs. OvX+Est) or experimental treatment (control vs. Indo vs. NS), 
mean values for EC50 or maximal response without common superscript are significantly 
different (P  0.031). Data are derived from Fig. 13, 16, 17. 
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middle and higher concentrations (Fig. 12, Table 3). The maximal contractile response 
was reduced by 43% (3,176 ± 179 mg/mg ring wt., P < 0.001) and 41% (3,258 ± 152 
mg, P < 0.001) by Indo and NS respectively, compared to the vehicle-control group 
(5,567 ± 276 mg). Sensitivity (EC50) of the female aorta to VP (8.0 ± 1.2 nM) was 
unchanged after pretreatment with either Indo (6.1 ± 0.4 nM, P = 0.165) or NS (10.9 ±  
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Fig. 12. Concentration-response curves for vasopressin in endothelium-intact aortic rings 
from intact (InT) female (F) Sprague-Dawley rats, in the presence of indomethacin (Indo, 
10 µM), NS-398 (NS, 10 µM) or vehicle-control (Veh). Data points represent means ± 
SE (n, no. of animals). Statistically significant differences exist in Veh vs. Indo (*, 
0.0001  P  0.048) and Veh vs. NS  (#, 0.0001  P  0.009) at both maximal (1 x 10-6 
M) and middle (1 x 10-8 M) concentrations of VP. A statistically significant difference 
exists in Indo vs. NS (P = 0.032) at middle but not maximal concentration of VP (P = 
0.736). 
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1.6 nM, P = 0.180; Table 3). A chemically dissimilar COX-2-selective inhibitor, 
niflumic acid, produced similar attenuating effects (2,376 ± 265 mg, P < 0.001) as NS on 
the contractile responses to VP (Fig. 13). 
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Fig. 13. Concentration-response curves for vasopressin in endothelium-intact aortic rings 
from intact (InT) female (F) Sprague-Dawley rats, in the presence of NS-398 (NS, 10 
µM), niflumic acid (NA, 10 µM), or vehicle-control (Veh). Data points represent means 
± SE (n, no. of animals). Statistically significant differences exist in Veh vs. NS (*, 
0.048  P  0.0001) and in Veh vs. NA  (#, 0.021  P  0.004) at both maximal (1 x 10-6 
M) and middle (1 x 10-8 M) concentrations of VP.  
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4.1.2. Effects of OvX and estrogen replacement therapy on contractile responses of 
female rat aorta to VP 
Plasma 17β-estradiol concentration of InT-female rats averaged 43.9 ± 13.0 
pg/ml. OvX reduced plasma estradiol by 97% (1.3 ± 0.4 pg/ml, P < 0.05), whereas 
estrogen replacement therapy restored plasma 17β-estradiol (27.9 ± 5.6 pg/ml) to 
concentrations similar to those of InT-female rats (Table 4). 
 
 
Table 4. Plasma estrogen concentrations of male and intact, OvX and OvX+Est-female 
rats. 
 
Group Male (n=6) 
 
InT-F (n=5) 
 
OvX-F (n=13) 
 
OvX+Est-F (n=13) 
 
Plasma estrogen level (pg/ml) 1.5 ± 0.5b 43.9 ± 13.0a 1.3 ± 0.4b 27.9 ± 5.6a
 
Values are means ± SE; n, no. of animals. InT-F, intact female; OvX-F, 
ovariectomized female; OvX+Est-F, OvX+17β-estradiol-replaced female. a,b mean 
values without common superscript are significantly different (P < 0.05). 
 
 
In initial experiments with VP, OvX did not consistently alter contractile 
responses to VP, or the attenuating effects of Indo or NS. Similarly, in initial 
experiments with U-44619, OvX failed to attenuate the contractile responses of the 
female aorta to this agonist. These findings are consistent with previous studies using 
standard laboratory rat chow (70), and led to the consideration that dietary 
phytoestrogens, which are plant-derived, estrogen-like molecules, may be responsible 
for the inconsistency of the data. Phytoestrogens are reported to interact with the 
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estrogen receptor (135) and thus, may have masked the effects of OvX on vascular 
reactivity to VP and U-46619. As postulated, OvX-female rats fed with an alfalfa- and 
soy protein-free diet consistently exhibited attenuated contractile responses to VP 
throughout the concentration-response curve and the attenuating effects of Indo and NS 
were likewise abolished (Fig. 14, 15). In contrast, estrogen replacement therapy restored  
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Fig. 14. Concentration-response curves for vasopressin in endothelium-intact aortic rings 
from intact- (InT), OvX-, and OvX+Est-female (F) Sprague-Dawley rats. The OvX-
female rats were fed with phytoestrogen-free diet (diet). Data points represent means ± 
SE (n, no. of animals). Statistically significant differences exist in InT-F vs. OvX-F (*, 
0.005  P  0.0002) and OvX+Est-F vs. OvX-F  (*, P < 0.0001) at maximal (1 x 10-6 M) 
and middle (1 x 10-8 M) concentrations of VP.  No differences exist in InT-F vs. 
OvX+Est-F (P > 0.1). 
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Fig. 15. Concentration-response curves for vasopressin in endothelium-intact aortic rings 
from OvX-female (F) Sprague-Dawley rats, in the presence of indomethacin (Indo, 10 
µM), NS-398 (NS, 10 µM) or vehicle-control (Veh). The OvX-female rats were fed with 
phytoestrogen-free diet (diet). Data points represent means ± SE (n, no. of animals). No 
statistically significant differences exist in Veh vs. Indo (P > 0.088), Veh vs. NS (P > 
0.160), or Indo vs. NS (P > 0.521) at both maximal (1 x 10-6 M) and middle (1 x 10-8 M) 
concentrations of VP. 
 
 
 
the contractile responses to VP and the attenuating effects of Indo and NS (Fig. 14, 16). 
Maximal contractile responses to VP were reduced 55% by OvX (2,485 ± 394 mg, P < 
0.001) and restored by estrogen replacement therapy (5,059 ± 194 mg, P > 0.1), 
compared with the InT-female aorta (Table 3). In the InT-female aorta, the differences in 
maximal contractile responses among control (5,567 ± 276 mg), Indo- (3,176 ± 179 mg), 
and NS-treated aortas (3,258 ± 152 mg) were highly significant (P < 0.001) (Table 3); in  
contrast, in the OvX-female aortas, maximal contractile responses of control (2,485 ±  
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394 mg), Indo- (1,666 ± 182 mg), and NS-treated aortas (1,833 ± 171 mg) did not differ 
significantly (P > 0.05) (Table 3). With estrogen replacement therapy, significant 
differences in maximal contractile responses among control (5,059 ± 194 mg), Indo- 
(3,643 ± 264 mg), and NS-treated aortas (3,457 ± 261 mg) were restored (P < 0.001). 
Sensitivity to VP (EC50) was not altered by OvX and did not differ significantly among 
control, Indo-, or NS-treated aortas (P > 0.1; Table 3).  
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Fig. 16. Concentration-response curves for vasopressin in endothelium-intact aortic rings 
from OvX+Est-female (F) Sprague-Dawley rats, in the presence of indomethacin (Indo, 
10 µM), NS-398 (NS, 10 µM) or vehicle-control (Veh). Data points represent means ± 
SE (n, no. of animals). Statistically significant differences exist in vehicle-control vs. 
Indo (*, 0.0002  P  0.0003) and vehicle control vs. NS (#, P < 0.0001) at both maximal 
(1 x 10-6 M) and middle (1 x 10-8 M) concentrations of VP. No statistically significant 
differences exist in Indo vs. NS (P > 0.299). 
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4.1.3. Male-female differences in contractile responses to exogenous TxA2 and the 
role of the endothelium 
Contractile responses of Endo+ aortas to the stable TxA2 analog U-46619 were 
significantly higher in female than in male in the upper half of the concentration-
response curve (Fig. 17). The maximal contractile responses of the Endo+ aorta in 
female (5,040 ± 238 mg) were 40% higher than in male (3,679 ± 96 mg, P < 0.0001) 
(Fig. 17, Table 5). Deletion of the endothelium potentiated the contractile responses of  
 
 
Table 5. EC50 and corresponding maximal contractile responses to the thromboxane 
analog U-46619 in paired endothelium-intact and endothelium-denuded thoracic aortic 
rings of male, and intact-, OvX-, and OvX+Est-female (F) Sprague-Dawley rats. 
 Male (n=9) 
 
InT-F (n=8) OvX-F (diet) (n=7) 
 
OvX+Est-F (n=5) 
Group EC50 
(nM) 
Maximal 
contractile 
force (mg/mg 
ring wt) 
EC50 
(nM) 
Maximal 
contractile 
force 
(mg/mg 
ring wt) 
EC50 
(nM) 
Maximal 
contractile 
force 
(mg/mg 
ring wt) 
EC50 
(nM) 
Maximal 
contractile 
force 
(mg/mg 
ring wt) 
Endo+ 27.3 
± 
3.2cd
3,679 
± 
95.8e
34.7 
± 
2.2d
5,040 
± 
238h
30.3 
± 
2.8d
3,923 
± 
84.1e
 
38.5 
± 
9.3d
5,024 
± 
155h
Endo- 13.0 
± 
1.7a
4,099 
± 
174.4ef
20.4 
± 
2.6bc
5,599 
± 
227h
14.8 
± 
3.0ab
4,441 
± 
99.6fg
 
35.2 
± 
2.4d
4,976 
± 
353gh
Values are means ± SE (n, no. of animals). EC50, concentration of agonist 
producing 50% of the maximal contractile response; Endo+, endothelium-intact; Endo-, 
endothelium-denuded. a-g within columns and rows for each group (Male vs. InT-F vs. 
OvX-F vs. OvX+Est-F) or experimental treatment (Endo+ vs. Endo-), mean values for 
EC50 or maximal response without common superscript are significantly different (P  
0.029). Data are derived from Fig. 17, 18. 
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Fig. 17. Concentration-response curves for U-46619 in endothelium-intact (Endo+) and 
endothelium-denuded (Endo-) aortic rings from intact (InT) female (F) and male (M) 
Sprague-Dawley rats. Data points represent means ± SE (n, no. of animals). Statistically 
significant differences exist in InT-F Endo+ vs. M Endo+ (*, P < 0.001) and InT-F 
Endo- vs. M Endo- (#, P < 0.001) at both maximal (3 x 10-6 M) and middle (1 x 10-7 M) 
concentrations of U-46619.  No statistically significant differences exist in Endo+ F vs. 
Endo- F (P = 0.111) and Endo+ M vs. Endo- M (P = 0.051) at maximal concentrations 
of U-46619. Statistically significant differences exist in Endo+ F vs. Endo- F (+, P = 
0.012) and Endo+ M vs. Endo- M (-, P = 0.008) at middle concentrations of U-46619. 
 
 
 
both female and male rat aortas to a similar extent; thus, contractile responses of Endo- 
female (5,599 ± 227 mg) were 37% greater than those of Endo- male (4,099 ± 174 mg, P 
< 0.0001) (Fig. 17, Table 5). Sensitivity (EC50) to U-46619 in the Endo+ aorta did not 
differ significantly between female (34.7 ± 2.2 nM) and male (27.3 ± 3.2 nM, P > 0.05). 
Deletion of the endothelium significantly increased the sensitivity of both female (20.4 ± 
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2.6 nM, P = 0.0009) and male (13.0 ± 1.7 nM, P = 0.0012) aortas, and the sensitivity to 
U-46619 in Endo- aorta was higher in male than in InT-female (P = 0.028) (Table 5). 
 
4.1.4. Effects of estrogen on female vascular reactivity to U-46619 
OvX noticeably attenuated the contractile responses of the female Endo+ aorta to 
U-46619. The maximal response to U-46619 was attenuated by 22% (3,923 ± 84 mg, P 
< 0.01) (Fig. 18, Table 5), compared to the InT-female aorta (5,040 ± 238 mg). Estrogen 
replacement therapy restored the contractile responses to U-46619 (4,976 ± 353 mg) in 
Endo+ aorta to levels similar to those of InT-female rat aortas (Fig. 18, Table 5). OvX 
had no effects on the sensitivity (EC50) of the Endo+ aorta to U-46619 (P > 0.1) (Table 
5). 
 
4.1.5. Effects of dietary phytoestrogens on the contractile responses of the rat aorta 
to VP and U-46619 
In OvX-female rats that were fed with standard rat chow diet, contractile 
responses to U-46619 fell between the curves for InT-female and male at middle and 
higher concentrations (Fig. 19). The maximal contractile response of the OvX-female 
aorta (4,472 ± 163 mg) was reduced by 11%, but was not significantly different from 
that of the InT-female aorta (5,040 ± 238 mg, P = 0.063) but was significantly higher 
than that of the male aorta (3,679 ± 95.8 mg, P < 0.001). In order to examine the role of 
male sex steroids in regulating the contractile responses to U-46619, male rats were 
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Fig. 18. Concentration-response curves for U-46619 in endothelium-intact (Endo+) 
aortic rings from intact- (InT), OvX-, and OvX+Est-female (F) Sprague-Dawley rats. 
The OvX-female rats were fed with phytoestrogen-free diet (diet). Data points represent 
means ± SE (n, no. of animals). Statistically significant differences exist in InT-F vs. 
OvX-F (*, 0.001  P  0.002) and OvX+Est-F vs. OvX-F  (#, 0.031  P  0.0001) at 
both maximal (3 x 10-6 M) and middle (1 x 10-7 M) concentrations of U-46619. No 
statistically significant differences exist in InT-F vs. OvX+Est-F (0.307  P  0.963) at 
both maximal (3 x 10-6 M) and middle (1 x 10-7 M) concentrations of U-46619. 
 
 
 
 
castrated at 4 weeks age and a concentration-response to U-46619 was obtained at 14-18 
weeks age (as in intact male rats). Surprisingly, contractile responses of both Endo+ and 
Endo- male aortas to U-46619 were unaffected by castration (Fig. 20). In contrast, the 
phytoestrogen-free diet further attenuated contractile responses of the OvX-female aorta 
to U-46619 at both middle and maximal concentrations by 16% and 22%, respectively, 
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so that OvX-female response did not differ from those of male aorta, but were 
significantly lower than responses of InT-female aorta (P < 0.01, Fig. 19). The maximal 
contractile response to U-46619 in the OvX-female aorta on the standard diet and on the 
special diet did not differ significantly (4,472 ± 163 mg vs. 4,182 ± 95.3 mg 
respectively, P > 0.05). InT-female rats fed with the phytoestrogen-free diet until 14-18  
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Fig. 19. Concentration-response curves for U-46619 in endothelium-intact (Endo+) 
aortic rings from male (M), intact- (InT), and OvX-female (F) Sprague-Dawley rats fed 
with standard rat chow or phytoestrogen-free diet (diet). Data points represent means ± 
SE (n, no. of animals). Statistically significant differences exist in InT-F vs. M  (*, P < 
0.001), InT-F vs. OvX-F fed with special diet (#, P < 0.01), and OvX-F fed with standard 
rat chow vs. M (+, P < 0.001) at maximal (3 x 10-6 M) concentrations of U-46619. No 
statistically significant differences exist in InT-F vs. OvX-F fed with standard rat chow 
(P = 0.063) at maximal (3 x 10-6 M) concentrations of U-46619. 
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Fig. 20. Concentration-response curves for U-46619 in endothelium-intact (Endo+) and 
endothelium-denuded (Endo-) aortic rings from intact (InT) and castrated (CsX) male 
(M) Sprague-Dawley rats. Data points represent means ± SE (n, no. of animals). No 
statistically significant differences exist in Endo+ M vs. Endo+ CsX-M (P =0.612)), 
Endo- M vs. Endo- CsX-M (P = 0.408) or Endo+ CsX-M vs. Endo- CsX-M (P = 0.653), 
at maximal concentrations of U-46619.  
 
 
 
weeks age exhibited slightly lower contractile responses to U-46619 compared to the 
InT-female rats fed with standard diet, but the differences were not significant (4,629 ± 
158 mg vs. 5,040 ± 238 mg, respectively, P > 0.1).  
 
The effects of the phytoestrogen-free diet on the contractile responses of female 
rat aorta to VP were discussed in section 4.1.2. 
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4.2. Specific aim 2: To determine male-female differences in TxA2 and PGI2 release 
by the rat aorta in vitro and the role of estrogen in the regulation of the TxA2 
and PGI2 biosynthesis pathway 
4.2.1. Male-female differences in basal and agonist-stimulated release of TxA2 and 
PGI2
Basal release of TxB2 did not differ significantly between InT-female (20.2 ± 4.2 
pg/mg ring wt./45 min) and male (18.8 ± 1.9 pg, P = 0.388) rat aortas (Fig. 21, Table 6).  
VP stimulated TxB2 release in a concentration-dependent manner, and both low (1 x 10-8 
M and high (1 x 10-6 M) concentrations of VP stimulated significantly more release of 
TxB2 by female than by male rat aortas. In InT-female, low and high concentration of 
VP increased TxB2 release by 121% (44.6 ± 7.0 pg, P = 0.006) and 334% (87.7 ± 12.7 
pg, P < 0.001), respectively, compared to basal release (20.2 ± 4.2 pg) (Fig. 21, Table 6). 
In contrast, in the male aorta, the low concentration of VP increased TxB2 release by 
only 37% (25.7 ± 4.2 pg), and the high concentration of VP increased TxB2 release by 
only 134% (43.9 ± 8.3 pg). The low-dose VP-stimulated release of TxB2 in the male 
aorta did not differ significantly from the basal group (18.8 ± 1.9 pg, P = 0.08); whereas 
the high VP-stimulated release of TxB2 did differ from the basal group (P = 0.014). 
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Table 6. Basal and low (10-8 M) or high (10-6 M) concentration VP-stimulated release of 
TxB2 and 6-keto-PGF1α from male, intact- (InT), OvX-, and OvX+Est-female (F) rat 
aortas. 
Group TxB2 (pg/mg ring wt./45 min) 
 
6-keto-PGF1α (pg/mg ring wt./45 min) 
 
 Basal Low-conc. 
VP (10-8 M) 
High-conc.  
VP (10-6 M) 
Basal Low-conc. 
VP (10-8 M) 
High-conc.  
VP (10-6 M) 
InT-F 
(n=7) 20.2±4.2ab 44.6±7.0c 87.7±12.7d 1,488±123a 3,860±800bc
12,646± 
2,683d
       
Male 
(n=6) 18.8±1.9ab 25.7±4.2b 43.9±8.3c 1,723±153a 2,811± 184b
5,155± 
1,046c
       
OvX-F 
(n=6) 17.4±1.7a 23.7±2.3b 38.2±4.2c 1,316±128a 2,107± 38ab 4,228± 520c
       
OvX+Est-F 
(n=6) 28±2.4b 56.9±9.3c 91±9.5d 1,746±415a 3,807±790bc
16,071± 
2,247d
 
Values are means ± SE (n, no. of animals). a-d for each animal group (InT-F vs. Male vs. 
OvX-F vs. OvX+Est-F) and for each treatment group (Basal vs. Low-dose vs. High-
dose), mean values for TxB2 or 6-keto-PGF1α without common superscript are 
significantly different (0.05 > P > 0.0001). conc., concentration. Data are derived from 
Fig. 21, 22. 
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Fig. 21. Basal and VP-stimulated (Low-dose, 10-8 M, or high-dose, 10-6 M) release of 
TxB2 by aortic rings prepared from male, intact- (InT), OvX- and OvX+Est-female (F) 
rats. Data points represent means ± SE (n, no. of animals). a-d For each group (male vs. 
InT-F vs. OvX-F vs. OvX+Est-F) and treatment (basal vs. Low vs. High), mean values 
for TxB2 release without common superscript are significantly different (0.05 > P > 
0.0001).  
 
 
 
Basal release of 6-keto-PGF1α did not differ significantly between InT-female 
(1,488 ± 123 pg/mg ring wt./45 min) and male (1,723 ± 153 pg, P = 0.388) rat aorta 
(Fig. 22, Table 6). VP also stimulated the release of 6-keto-PGF1α in a concentration- 
dependent manner. Compared to basal, both low and high concentrations of VP 
stimulated significantly more release of 6-keto-PGF1α in both InT-female and male rat 
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Fig. 22. Basal and VP-stimulated (Low-dose, 10-8 M, or high-dose, 10-6 M) release of 6-
keto-PGF1α by aortic rings prepared from male, intact- (InT), OvX- and OvX+Est- 
female (F) rats. Data points represent means ± SE (n, no. of animals). a-d For each group 
(male vs. InT-F vs. OvX-F vs. OvX+Est-F) and treatment (basal vs. Low vs. High), mean 
values for 6-keto-PGF1α release without common superscript are significantly different 
(0.05 > P > 0.0001).  
 
 
 
aortas, although responses of female aorta were substantially greater. In all four 
experimental groups, VP stimulated the release of substantially more 6-keto-PGF1α than 
TxB2 (Table 6). In InT-female, low and high concentrations of VP increased the release 
of 6-keto-PGF1α by 159% (3,860 ± 800 pg, P = 0.013) and 750% (12,646 ± 2683 pg, P < 
0.001), respectively, compared to the basal group (1,488 ± 123 pg) (Fig. 22, Table 6). In 
male, low and high concentrations of VP increased the release of 6-keto-PGF1α by 63% 
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(2,811 ± 184 pg, P = 0.002) and 199% (5,155 ± 1,046 pg, P = 0.012), respectively, 
compared to the basal group. 
 
4.2.2. Effects of OvX and estrogen replacement therapy on the release of TxA2 and 
PGI2
OvX and estrogen replacement therapy had no effects on basal release of either 
TxB2 or 6-keto-PGF1α (Fig. 21, 22, Table 6). In contrast, OvX significantly decreased 
both low- (23.7 ± 2.3 pg, P = 0.011) and high- (38.2 ± 4.2 pg, P = 0.003) concentration 
VP-stimulated release of TxB2 to levels similar to those of male rats, while estrogen 
replacement therapy restored both low- and high-concentrations VP-stimulated release 
of TxB2 to levels not different from those of InT-female (Fig. 21, Table 6). Low-
concentration VP-stimulated release of 6-keto-PGF1α, while reduced by OvX and 
increased by estrogen replacement therapy, did not differ significantly between InT-
female (3,860 ± 800 pg) and OvX-female (2,107 ± 386 pg, P = 0.089) or between OvX-
female and OvX+Est-female (3,807 ± 790 pg, P = 0.082) rat aortas (Fig. 22, Table 6). 
High concentration VP-stimulated release of 6-keto-PGF1α was reduced significantly 
(67%) by OvX (4,228 ± 520 pg, P = 0.016) to levels similar to those of male rats (5,155 
± 1046 pg) and was restored by estrogen replacement therapy (16,071 ± 2,247 pg) to 
levels similar to those of the InT-female aorta (Fig. 22, Table 6). 
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4.2.3.  Effects of COX and TxS inhibition and estrogen on the release of TxA2 and 
PGI2
The non-selective COX inhibitor Indo (10 µM) and the COX-2-selective 
inhibitor NS-398 (10 µM) both significantly inhibited the release of TxB2 and 6-keto-
PGF1α from male, InT-female and OvX-female rat aortas (Fig. 23, 24, Table 7). Indo 
inhibited TxB2 release to a similar extent in InT-female (91% ± 3%), male (95% ± 2%) 
and OvX-female (86% ± 4%) aortas (P > 0.08). NS inhibited TxB2 release to a similar 
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Fig. 23. High-dose (10-6 M) VP-stimulated release of TxB2 by aortic rings prepared from 
InT-F, male and OvX-F rats, in the presence of indomethacin (Indo, 10 µM), NS-398 
(NS, 10 µM) or vehicle-control (Veh). Data bars represent means ± SE (n, no. of 
animals). a-e For each group (InT-F vs. male vs. OvX-F) and treatment (Veh vs. Indo vs. 
NS), mean values for TxB2 release without common superscript are significantly 
different (0.0001  P  0.03).  
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Fig. 24. High-dose (10-6 M) VP-stimulated release of 6-keto-PGF1α by aortic rings 
prepared from InT-F, male and OvX-F rats, in the presence of indomethacin (Indo, 10 
µM), NS-398 (NS, 10 µM) or vehicle-control (Veh). Data bars represent means ± SE (n, 
no. of animals). a-d For each group (InT-F vs. male vs. OvX-F) and treatment (Veh vs. 
Indo vs. NS), mean values for 6-keto-PGF1α  release without common superscript are 
significantly different (0.0001  P  0.004).  
 
 
 
extent in InT-female (90% ± 3%) and male (86% ± 4%) (P = 0.44), but inhibited 
significantly less TxB2 release in OvX-female (76% ± 3%) compared to InT-female (P = 
0.009) or male aortas (P = 0.033). Indo inhibited significantly more 6-keto-PGF1α 
release in InT-female (97% ± 1%) and male (99% ± 0%) than in OvX-female (78% ± 
5%) (P < 0.002). NS inhibited more 6-keto- PGF1α release in InT-female (84%) than in 
male (69%, P = 0.002) or OvX-female (76%, P = 0.086).  
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Table 7. High (10-6 M) concentration of VP-stimulated release of TxB2 and 6-keto-
PGF1α  from male, intact-, and OvX-female (F) rat aortas in the presence of vehicle-
control (Veh), indomethacin (Indo, 10 µM), or NS-398 (NS, 10 µM). 
 
 
Group TxB2  (pg/mg ring wt./45 min) 
 
6-keto-PGF1α  (pg/mg ring wt./45 min) 
 
 Veh Indo 
(10 µM) 
NS 
(10 µM) 
Veh Indo 
(10 µM) 
NS 
(10 µM) 
 
InT-F 
(n=5) 70.4±12.6d 4.6±1.1a 7.9±1.5b 15,134±4,699e 323±34.2b 1,040±151c
 
Male 
(n=5) 32.1±11c 1.6±1.0a 6.1±1.9b 4,223±1,329d 11.0±4.1a 825±72.7c
 
OvX-F 
(n=5) 29.9±2.9c 3.8±0.9a 7.0±0.8b 4,328±484d 891.4±139c 958±79.1c
 
Values are means ± SE (n, no. of animals). a-d for each animal group (InT-F vs. 
Male vs. OvX-F) and for each treatment group (Veh vs. Indo vs. NS), mean values for 
TxB2 and 6-keto-PGF1α without common superscript are significantly different (0.0001 
 P 0.04).  Data are derived from Fig. 23, 24. 
 
 
 
The TxS inhibitor DAZ (50 µM) inhibited high-concentration VP-stimulated 
TxB2 release from male, InT-female, OvX-female and OvX+Est-female rat aortas 
significantly (P  0.008) (Fig. 25, Table 8). In contrast, DAZ increased the release of 6-
keto-PGF1α in all four experimental groups significantly (P  0.015) (Fig. 26, Table 8). 
The inhibitory effect of DAZ on TxB2 release was slightly higher in InT-female (79% ± 
3%) and OvX+Est-female (77% ± 3%) than in male (74% ± 2%) and OvX-female (70% 
± 9%), but the differences were not statistically significant (P > 0.11). Interestingly, 
DAZ did not decrease, but rather increased 6-keto- PGF1α release in all four 
experimental groups. DAZ only increased 6-keto-PGF1α release by 66% ± 11% in InT-
female and 42% ± 17% in OvX+Est-female, respectively (P = 0.12), while it increased 
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6-keto- PGF1α release by 298% ± 52% in male and by 178% ± 57% in OvX-female, 
which were markedly higher than InT-female (P  0.015). 
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Fig. 25. High-dose (10-6 M) VP-stimulated release of TxB2 by aortic rings prepared from 
male, InT-F, OvX-F, and OvX+Est-F rats, in the presence of dazoxiben (DAZ, 50 µM) 
or vehicle-control (Veh). Data bars represent means ± SE (n, no. of animals). a-c For each 
group (InT-F vs. male vs. OvX-F vs. OvX+Est-F) and treatment (Veh vs. DAZ), mean 
values for TxB2 release without common superscript are significantly different (0.0001  
P  0.03).  
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Fig. 26. High-dose (10-6 M) VP-stimulated release of 6-keto-PGF1α by aortic rings 
prepared from male, InT-F, OvX-F, and OvX+Est-F rats, in the presence of dazoxiben 
(DAZ, 50µM) or vehicle-control (Veh). Data bars represent means ± SE (n, no. of 
animals). a-c For each group (InT-F vs. male vs. OvX-F vs. OvX+Est-F) and treatment 
(Veh vs. DAZ), mean values for 6-keto-PGF1α release without common superscript are 
significantly different (0.0001  P  0.033). 
 
 
 
Table 8. High (10-6 M) concentration of VP-stimulated release of TxB2 and 6-keto-
PGF1α from male and InT-, OvX-, and OvX+Est-female (F) rat aortas in the presence of 
vehicle-control (Veh), or dazoxiben (DAZ, 50 µM). 
 
Group TxB2 (pg/mg ring wt./45 min) 
 
6-keto-PGF1α (pg/mg ring wt./45 min) 
 
 Veh DAZ (50 µM) Veh DAZ (50 µM) 
 
InT-F (n=7) 77.7±5.2c 15.7±1.3a 12,888±765 e 21,039±1,168 f
Male (n=5) 54.1±6.1b 13.7±1.6 a 4,703±956 d 17,111±2,457ef
OvX-F (n=4) 42.9±7 b 10.9±2 a 5,540±720 d 14,219±1,237e
OvX+Est-F (n=5) 77.5±11.7 c 16.7±1.4 a 13,983±1,094 e 19,180±1,265 f
 
Values are means ± SE (n, no. of animals). a-c for each animal group (InT-F vs. 
Male vs. OvX-F vs. OvX+Est-F) and for each treatment group (Veh vs. DAZ), mean 
values for TxB2 and 6-keto-PGF1α without common superscript are significantly 
different (0.0001  P  0.033). Data are derived from Fig. 25, 26. 
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4.3. Specific aim 3: To determine the molecular mechanism(s) by which estrogen 
upregulates constrictor prostanoid function in the rat aorta 
4.3.1. The mRNA levels of COX-1, COX-2 and TxS by rat aorta and the effects of 
OvX and estrogen replacement therapy on their expression 
RT-PCR measurements showed that COX-1 mRNA was expressed in both aortic 
endothelial (Endo) and VSM cells. There were no statistical differences between the 
male and female COX-1 mRNA expression in either Endo (0.203 ± 0.044 and 0.193 ± 
0.043, respectively, P = 0.879) or VSM (0.463 ± 0.113 and 0.440 ± 0.087, respectively, 
P = 0.879). OvX and estrogen replacement therapy had no effect on COX-1 mRNA 
expression in either aortic Endo or VSM (Fig. 27, 28, Table 9). 
COX-2 mRNA was expressed in both aortic Endo and VSM. In contrast to the 
findings for COX-1, the female rat aorta expressed significantly more COX-2 mRNA in 
both Endo (0.360 ± 0.1, P = 0.046) and VSM (0.450 ± 0.064, P = 0.002) compared to 
male (0.050 ± 0.040 and 0.052 ± 0.032, respectively). OvX markedly attenuated the 
COX-2 mRNA expression by 79% in both Endo (0.077 ± 0.047, P = 0.031) and VSM 
(0.093 ± 0.018, P = 0.006), to levels similar to those detected in male. Estrogen 
replacement therapy restored COX-2 mRNA expression in both Endo (0.410 ± 0.071, P= 
0.705) and VSM (0.333 ± 0.062, P = 0.258) to levels that did not differ from those in the 
InT-female aorta (Fig. 28, 29, Table 9). 
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Table 9. The expression of COX-1, COX-2, TxS, and TP mRNA in vascular 
endothelium (Endo) or vascular smooth muscle (VSM) cells prepared from male, InT-F, 
OvX-F and OvX+Est-F rat aortas, measured by RT-PCR. 
 
Endo 
 
COX-1 
 
COX-2 
 
TxS 
 
 
 
InT-F (n=3) 0.20±0.04 a 0.36±0.1c 0.38±0.12e  
 
Male (n=4) 0.2±0.04 a 0.05±0.04d 0.1±0.06f
 
 
OvX-F (n=4) 0.15±0.04 a 0.08±0.05 d 0.09±0.07 f
 
 
OvX+Est-F (n=3) 0.14±0.04 a 0.41±0.07 c 0.39±0.02 e
 
 
VSM 
 
COX-1 
 
COX-2 
 
TxS 
 
TP 
 
 
InT-F (n=3) 0.44±0.09b 0.45±0.06 c 0.25±0.02 e 0.44±0.04g
 
Male (n=4) 0.46±0.11 b 0.05±.0.03 d 0.09±0.02 f 0.27±0.03h
 
OvX-F (n=4) 0.49±0.09 b 0.09±0.02 d 0.07±0.01 f 0.26±0.04 h
 
OvX+Est-F (n=3) 0.48±0.05 b 0.33±0.06 c 0.36±0.12 e 0.37±0.03 g
 
Values are expressed as the ratio of specific mRNA to the expression of GAPDH 
mRNA from the same tissue. Data points represent means ± SE (n, no. of animals). a-d 
For each specific mRNA (COX-1, COX-2, TxS, or TP), mean values for each animal 
group (male vs. InT-F vs. OvX-F vs. OvX+Est-F) and each treatment (Endo vs. VSM) 
without common superscript are significantly different (0.05 >P > 0.0001). Data are 
derived from Fig. 27, 29, 30. 
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Fig. 27. The expression of COX-1 mRNA levels in vascular endothelium (Endo) and 
vascular smooth muscle (VSM) cells obtained from male, InT-F, OvX-F and OvX+Est-F 
rat aortas. The OvX-F rats were fed with phytoestrogen-free diet (diet). Values are 
expressed as the ratio of COX-1 mRNA to GAPDH mRNA level obtained from the 
same tissues. Data bars represent means ± SE (n, no. of animals). a-b, For each group 
(InT-F vs. M vs. OvX-F vs. OvX+Est-F) and treatment (Endo vs. VSM), mean values for 
COX-1 mRNA expression levels without common superscript are significantly different 
(P < 0.05). No statistically significant differences exist among the four experimental 
groups in either Endo (P ≥ 0.39) or VSM (P ≥ 0.69). 
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Fig. 28. The RT-PCR gel for COX-1, COX-2, TxS and TP from aortic Endo and VSM 
cells obtained from male (M), intact female (InT), ovariectomized female (OvX), and 
estrogen replaced female (Est) rat aortas. The OvX-female rats were fed with 
phytoestrogen-free diet. The first lane on each gel was the standard DNA ladder. bp, the 
size of RT-PCR products. 
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Fig. 29. The expression of COX-2 mRNA levels in vascular endothelium (Endo) and 
vascular smooth muscle (VSM) cells obtained from male, InT-F, OvX-F and OvX+Est-F 
rat aortas. The OvX-F rats were fed with phytoestrogen-free diet. Values are expressed 
as the ratio of COX-2 mRNA to GAPDH mRNA level obtained from the same tissues 
(%COX-2/GAPDH. Data bars represent means ± SE (n, no. of animals). a-b, mean values 
among the four experimental groups (Male, InT-F, OvX-F and OvX+Est-F) and the two 
tissue (Endo vs. VSM) without common script are significantly different (0.002  P  
0.03).  
 
 
Similar to COX-2, TxS mRNA was expressed in both aortic Endo and VSM, and 
the female rat aorta expressed significantly higher TxS mRNA in both Endo (0.380 ± 
0.123, P = 0.04) and VSM (0.252 ± 0.015, P < 0.001) than the male aorta (0.102 ± 0.063 
and 0.090 ± 0.017, respectively). OvX markedly attenuated TxS mRNA expression by 
78% in Endo (0.085 ± 0.072, P = 0.039) and 72% VSM (0.070 ± 0.010, P < 0.001) to 
levels similar to those observed in male. Estrogen replacement therapy restored TxS 
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mRNA expression in both Endo (0.387 ± 0.018, P =0.960) and VSM (0.363 ± 0.117, P 
=0.316) to levels not different from those detected in InT-female (Figure 28, 30, Table 9). 
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Fig. 30. The expression of TxS mRNA levels in vascular endothelium (Endo) and 
vascular smooth muscle (VSM) cells obtained from male, InT-F, OvX-F and OvX+Est-F 
rat aortas. The OvX-F rats were fed with phytoestrogen-free diet (diet). Values are 
expressed as the ratio of TxS mRNA to GAPDH mRNA level obtained from the same 
tissues (%TxS/GAPDH). Data bars represent means ± SE (n, no. of animals). a-b, mean 
values among the four groups (InT-F vs. M vs. OvX-F vs. OvX+Est-F) and the two 
tissues (Endo vs. VSM) without common script are significantly different (0.0003  P  
0.04). 
 
 
4.3.2. The protein expression of COX-1, COX-2 and TxS enzymes and the effects of 
OvX and estrogen replacement therapy on enzyme expression 
Immunohistochemistry studies provided a way to quantify COX-1, COX-2 and 
TxS protein expression in the aortic wall. Qualitatively, there was no stain observed on 
the endothelium from the control group. Very light and similar levels of staining for 
COX-1 were observed in all four experimental groups. The staining for COX-2 protein 
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was more obvious on the endothelium of InT-female and OvX+Est-female than of male 
and OvX-female aortas. Darker staining for TxS was observed on the endothelium of 
InT-female and OvX+Est-female than on male and OvX-female aortas (Fig. 31). Since 
protein staining on the thin endothelial layer could not be accurately scored, protein 
expression was quantitatively scored only in VSM. In VSM, there were no statistically 
significant differences in COX-1 staining between female (3.6 ± 0.1) and male (3.5 ± 
0.2). OvX and estrogen replacement therapy had no effects on COX-1 expression. In 
contrast, significantly more staining for COX-2 was observed in the female aorta (2.9 ± 
0.5) than in the male aorta (1.6 ± 0.4, P = 0.041). OvX markedly attenuated COX-2 
protein expression (1.067 ± 0.133, P = 0.011), and estrogen replacement therapy restored 
the staining for COX-2 (3.067 ± 0.521, P = 0.849) (Fig. 31, Table 10). Similar to the 
pattern of COX-2 protein expression, significantly more staining for TxS was observed 
in the female aorta (2.75 ± 0.52) than in the male aorta (1.425 ± 0.253, P = 0.031). OvX 
markedly attenuated the TxS protein expression (1.20 ± 0.235, P = 0.017), and estrogen 
replacement therapy restored the staining for TxS (2.05 ± 0.166, P = 0.247) (Fig. 31, 
Table 10).  
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Fig. 31. Immunohistochemical stain (brown color) for COX-1, COX-2 and TxS protein 
expression in aortic smooth muscle prepared from male, InT-F, OvX-F (fed with 
phytoestrogen-free diey) and OvX+Est-F rat aortas. Control panel was stained with same 
procedure but without primary antibody. Blue color showed the counterstain with 
hematoxylin. 
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Fig. 31. (Continued) 
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Table 10. The protein expression of COX-1, COX-2, and TxS in aortic VSM prepared 
from male, InT-F, OvX-F and OvX+Est-F rat aortas, as measured by 
immunohistochemistry. 
 
Group InT-F (n=4) 
 
Male (n=5) 
 
OvX-F (n=4) 
 
OvX+Est-F (n=3) 
 
COX-1 3.6±0.1a 3.5±0.2 a 3.7±0.2 a 3.2±0.3 a
COX-2 2.9±0.5b 1.6±0.4c 1.1±0.1 c 3.1±0.5 b
TxS 2.8±0.5d 1.4±0.3e 1.2±0.2 e 2.1±0.2 d
 
Values are expressed as scores of immunohistochemical stains for COX-1, 
COX-2, or TxS protein. Data points represent means ± SE (n, no. of animals). a-e for 
each specific protein (COX-1, COX-2 or TxS), mean values without common 
superscript are significantly different among four experimental groups (male vs. InT-F 
vs. OvX-F vs. OvX+Est-F) (0.041 > P > 0.011). 
 
 
 
4.3.3. The expression of the TP mRNA by rat VSM cells and the effects of OvX and 
estrogen replacement therapy on TP expression 
mRNA expression of the TP in aortic VSM was measured by RT-PCR. TP 
mRNA level was significantly higher in the female (0.51 ± 0.04) than in the male (0.27 ± 
0.03, P= 0.004). OvX markedly attenuated TP mRNA expression in the female rat aorta 
(0.26 ± 0.04, P = 0.010), while estrogen replacement therapy restored receptor 
expression to a level similar to that of the InT-female aorta (0.37 ± 0.03, P = 0.102) (Fig. 
28, 32, Table 10).  
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Fig. 32. The expression of PGH2/TxA2 receptor (TP) mRNA levels in vascular smooth 
muscle (VSM) prepared from male, InT-F, OvX-F and OvX+Est-F rat aortas. Values are 
expressed as the ratio of TR mRNA to GAPDH mRNA level obtained from the same 
tissue (%TP/GAPDH). Data bars represent means ± SE (n, no. of animals). a-b, mean 
values among the four groups (InT-F vs. M vs. OvX-F vs. OvX+Est-F) without common 
script are significantly different (0.008  P  0.019). 
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CHAPTER V 
DISCUSSION 
 
In the present studies, OvX and estrogen replacement therapy were used to 
determine the role of estrogen in the regulation of vascular reactivity to VP and 
constrictor prostanoid potentiation of the vascular responses to VP. Selective COX 
inhibitors were used to determine the role of COX isozymes in the sex differences in 
vascular reactivity to VP. To determine the contribution of constrictor prostanoid release 
to male-female differences in aortic reactivity to VP, basal and VP-stimulated release of 
TxA2 and PGI2 were measured. The effects of estrogen on constrictor prostanoid (TxA2) 
release and aortic reactivity to TxA2 were also studied. Finally, the underlying molecular 
mechanisms of estrogen action on constrictor prostanoid pathway function were 
determined by measuring expression of COX-1, COX-2, TxS and TP mRNA by RT-
PCR and COX-1, COX-2, and TxS protein production by immunohistochemistry.  
The major findings derived from this study are: 1) Estrogen potentiates 
contractile responses of the female rat aorta to VP by upregulating COX-2, but not 
COX-1, function; 2) The contractile responses to U-46619 are significantly higher in 
female than in male rat aorta; and OvX attenuates, whereas estrogen replacement therapy 
restores, the contractile responses to U-46619 in female rat aorta; 3) VP-stimulated 
release of both TxA2 and PGI2 are higher in female than in male  rat aorta; and OvX 
decreases, whereas estrogen replacement therapy restores, both TxA2 and PGI2 release 
from female rat aorta; 4) Estrogen potentiates COX-2 , TxS and TP message and protein 
expression in both endothelium and VSM of the female rat aorta. 
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5.1. Effects of COX inhibitors on contractile responses of female rat aorta to VP 
Previous studies established that the contractile responses of the rat aorta to VP 
are threefold higher in female than in male (70, 224, 225, 226). Similar sex differences 
in the vascular reactivity to VP have been reported in mesenteric arterioles of 
anesthetized rats (5) and in the isolated, perfused rat mesenteric vasculature (227, 229). 
Previous studies also demonstrated that VP-stimulated release of NO is much greater in 
the male aorta and is responsible for the markedly attenuated responses to VP, compared 
to the female aorta (224, 225). Interestingly, even in the presence of NOS inhibition, 
contractile responses to VP are still higher in female, and several studies have revealed 
that this remaining sex difference in reactivity to VP involves constrictor prostanoids 
(70, 224). The non-selective COX inhibitor Indo and the TP antagonist SQ 29,548 both 
attenuated contractile responses of the female but not the male rat aorta to VP to the 
same extent (70), which established that constrictor prostanoids play a significant role in 
potentiating contractile responses of the female but not the male systemic vasculature to 
VP. However, these studies did not examine the underlying mechanisms of these sex 
differences in detail at the cellular or molecular levels.  
To further determine the role of constrictor prostanoids in VP-induced 
contraction of the female rat aorta, the effects of COX inhibitors were examined in the 
present study. The non-selective COX inhibitor Indo significantly attenuated the 
contractile responses of the female rat aorta to VP by 43%. Interestingly, the chemically 
dissimilar COX-2-selective inhibitors NS and NA both attenuated contractile responses 
to VP to a similar extent as Indo (41% and 46% respectively), which strongly suggests 
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that COX-2 but not COX-1 mediates at least in part, the constrictor prostanoid 
potentiation of the contractile responses of the female rat aorta to VP. Thus, the present 
study clearly establishes the involvement of COX-2 in the constrictor prostanoid-
mediated potentiation of the contractile responses of the systemic vasculature of the 
female but not the male to VP. 
COX-1 and COX-2 are two isoforms of the cyclooxygenase enzyme. Different 
genes encode these isoforms (131, 132). COX-1 is the constitutive isoform present in 
many cells and is a housekeeping enzyme (219, 255). Conversely, COX-2 is an 
inducible isoform activated by inflammatory agents (116, 186); however, COX-2 is also 
constitutively expressed in some tissues such as the kidney, lung, spinal cord and heart 
(180, 186, 254), and may play a role in regulating normal renal function and blood flow. 
The present study is the first to provide clear evidence that COX-2 is expressed 
constitutively in the rat aorta under normal physiological conditions, and is involved in 
the regulation of systemic vascular function in the female but not the male rat. 
 
5.2. Effects of OvX and estrogen replacement therapy on contractile responses of 
female rat aorta to VP 
To determine the role of estrogen in the regulation of constrictor prostanoid 
pathway function in the female rat aorta, the effects of OvX and estrogen replacement 
therapy on vascular reactivity to VP and prostanoid function were determined. Plasma 
17β-estradiol concentrations measured in the present study are consistent with those of 
previous studies (220, 250). Plasma concentrations of 17β-estradiol were attenuated 
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drastically in OvX-female rats, and did not differ from those of male rats. Estrogen 
replacement therapy restored plasma estrogen concentrations of OvX-female rats to 
levels not significantly different from those of InT-female rats (Table 4).  
OvX markedly attenuated contractile responses to VP in the female rat aorta on 
phytoestrogen-free diet, and abolished the inhibitory effects of both Indo and NS. In 
contrast, long-term (3 – 4 weeks) estrogen replacement therapy with 17β-estradiol in 
OvX-female rats completely restored both the contractile responses to VP and the 
inhibitory effects of Indo and NS. These results clearly establish that constrictor 
prostanoid potentiation of the contractile responses of the female rat aorta to VP is 
strongly dependent upon the action of estrogen on the vascular wall.  
Estrogen receptors have been identified in both the endothelium (7, 38, 41) and 
VSM (7, 173, 181); thus, the potentiating effect of estrogen on constrictor prostanoid 
function in the female aorta may involve actions on the endothelium and/or VSM. In the 
present study, pharmacological blockage of the prostanoid pathway at the level of COX 
suggests that the potentiating effect of estrogen involves upregulation of COX-2 and the 
subsequent constrictor prostanoid pathway, thereby regulating both the release and 
action of the constrictor prostanoids. 
 
5.3. Effects of estrogen on prostanoid biosynthesis pathway 
The present study revealed that VP stimulated production of TxA2 and PGI2 from 
both male and female rat aorta in a concentration-dependent manner, and that VP-
stimulated release of TxA2 and PGI2 was significantly higher in female than in male. 
97  
OvX attenuated and estrogen replacement therapy restored VP-stimulated release of 
TxA2 and PGI2 from the female rat aorta. These findings demonstrate that estrogen 
potentiates VP-stimulated release of TxA2 and PGI2 in female aorta. Numerous previous 
studies support the present finding that estrogen enhances vascular prostanoid 
production. For example, pretreatment of isolated, blood-perfused lungs of juvenile 
female sheep with estradiol enhances the production of TxA2 (235). Similarly, in the 
isolated, exogenous arachidonic acid perfused rat lung, production of PGI2 and TxA2, 
which reflects COX activity, varies during the course of the estrous cycle and peaks 
during the estrogen surge at proestrous (10). Further, estrogen treatment enhances TxA2 
production in rat endothelial cells (262) and PGI2 production in both rat VSM cells (34) 
and ovine fetal pulmonary artery endothelial cells (217). However, the present study is 
the first to establish the importance of estrogen in the regulation of vascular TxA2 
production by the systemic vasculature. 
The present study also revealed that the non-selective COX inhibitor, Indo, and 
the COX-2-selective inhibitor, NS, both attenuated the release of TxA2 to a similar 
extent (91% and 90%, respectively) by the female aorta. This finding is consistent with 
the equipotent attenuating effects of both Indo and NS on the contractile response to VP 
in the female aorta; thus, the present study is the first to demonstrate that estrogen 
potentiates VP-stimulated release of prostanoids by the female rat aorta, at least in part, 
by upregulating COX-2 function.  
In contrast to the findings on VP-stimulated release of TxA2 and PGI2, basal 
release of both TxA2 and PGI2 did not differ among the four experimental groups. One 
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explanation for this difference is that the enzymes involved in the biosynthesis of TxA2 
may exist in different cellular compartments and may function differently under basal 
and agonist-stimulated conditions, or that the enzymes have activated and inactivated 
forms. For example, COX-1 and COX-2 both exist in the endoplasmic reticulum and in 
the nuclear envelope (221); however, recent studies show that COX-2 also exists in the 
plasma membrane, complexed with caveolin-1 (149), and the concentration of COX-2 is 
twofold greater in nuclear envelope than in endoplasmic reticulum (166), especially 
localized at the perichromatin zone (187). Thus, it is possible that the potentiating effect 
of estrogen on the prostanoid biosynthesis pathway is different under basal and agonist-
stimulated conditions. Estrogen and agonists may work synergistically, or act differently 
than under basal conditions, to stimulate the expression of COX-2 that locates in a 
particular cellular compartment. It is also possible that estrogen-induced synthesis of 
enzyme molecules needs to be activated by an agonist, such as VP, to exert its catalytic 
function in TxA2 biosynthesis pathway. Further experiments should be done to elucidate 
the interaction of estrogen and agonists involved in prostanoid biosynthesis and the 
subcellular location of COX-2 stimulation. 
It is well known that estrogen can stimulate expression of eNOS and enhance NO 
release (98, 126, 259). The balance between vasodilation and vasoconstriction is very 
important for the regulation of vascular tone. The higher release of NO in the female 
vasculature (121, 129) may result in the need for mechanism(s) to counterbalance the 
vasodilator effect of NO; the co-existence of NOS and COX-2 in caveolin imply that 
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estrogen may play a role in counterbalancing the NO-vasodilatory mechanism by 
stimulating the production of constrictor prostanoids.  
TxA2 causes platelet aggregation, and is a vasoconstrictor. In contrast, PGI2 
prevents platelet aggregation and is a vasodilator. The balance between TxA2 and PGI2 is 
very important in the regulation of homeostasis of the circulatory system (29, 245); and 
an imbalance between TxA2 and PGI2 is associated with the pathogenesis of some 
cardiovascular diseases such as pulmonary hypertension and atherosclerosis (37, 76, 106, 
244). It is reported that injury-induced vascular proliferation and platelet activation are 
enhanced in mice that are genetically deficient in the PGI2 receptor, but are depressed in 
mice genetically deficient in the TP or treated with a TP antagonist (36). 
TxA2 and PGI2 are both derived from the same prostanoid metabolic intermediate 
PGH2, a COX product, by the actions of TxS and prostacyclin synthase, respectively, on 
PGH2. The present study uniquely revealed the dynamic characteristics of the prostanoid 
pathway as a whole, and that an interrelationship exists between TxA2 and PGI2 
synthesis within the prostanoid metabolic pathway. In the presence of the TxS inhibitor 
DAZ, VP-stimulated release of TxA2 was markedly attenuated, whereas, the production 
of PGI2 was increased. This finding reveals that with inhibition of the TxS pathway, 
accumulation of the common upstream intermediate PGH2 then alters the activity of the 
prostacyclin synthase pathway, enhancing the production of PGI2. Since PGI2 is an 
important local vasodilator and inhibitor of platelet aggregation, the present findings 
imply that TxS inhibitors may be an effective therapy for constrictor prostanoid-
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mediated systemic vascular diseases, not only by inhibiting the production of 
vasoconstrictor TxA2, but also by potentiating the production of vasodilator PGI2.  
Another interesting finding about the effects of DAZ on the release of TxB2 and 
6-keto-PGF1α is that DAZ tremendously increased 6-keto-PGF1α release in male (298%) 
and OvX-female (178%) aortas, but only increased 6-keto-PGF1α release by 66% in InT-
female and by 42% in OvX+Est-female aortas. It was reported that prolonged use of 
combined oral contraceptives was associated with decreased production of PG12 (268), 
and estrogen decreases PGI2 production in both intact and castrated male rats (39). Thus, 
the increased release of 6-keto-PGF1α in the presence of DAZ, especially the huge 
increase in male and OvX-female aortas implies that there may exist the combined 
inhibitory effect of TxA2 and estrogen on PGI2 production, perhaps via regulating PGI2 
synthase activity. So that in the presence of DAZ and loss of estrogen, the PGI2 synthesis 
is dramatically increased. 
 
5.4. Effects of estrogen on vascular reactivity to thromboxane 
The present study demonstrates that estrogen not only enhances the activity of 
COX-2 and the release of constrictor prostanoids, but also potentiates vascular reactivity 
to the constrictor prostanoid TxA2. Contractile responses to the TxA2 analog U-46619 
were significantly higher in female than in male aorta. This finding is consistent with the 
findings in the isolated rat pulmonary vasculature (65). In both past and present studies, 
OvX and phytoestrogen-free diet abolished and estrogen replacement therapy restored 
the contractile responses of the female vasculature to U-46619. These results reveal that 
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estrogen enhances contractile responses of female aorta to the constrictor prostanoid 
TxA2. The underlying mechanisms may include: 1) estrogen-induced increases in the 
density of TP in rat aortic VSM cells; 2) U-46619-stimulated release of vasoactive 
substance(s) from the vascular endothelium, which may be upregulated by estrogen; or 
3) estrogen-enhanced downstream signal transduction mechanisms is involved in TxA2-
stimulated VSM contraction. A previous study using cultured rat aortic VSM cells 
reported that the total number of TxA2 binding sites per cell is higher in female than in 
male VSM cells (155); however, the investigators did not examine reactivity of the 
female aorta to TxA2. Therefore, it is possible that the greater contractile responses to U-
46619 in the female rat in the present study, especially in Endo- aortic rings, may 
involve upregulation of TP expression by estradiol in VSM cells.  Concentration-
response curves with paired Endo+ and Endo- aortic rings in the present study revealed 
that deletion of the endothelium increased contractile responses to U-46619 in both male 
and female, but the effect of de-endothelialization did not differ between male and 
female. The increase in contractile responses to U-46619 after removal of the 
endothelium may be due to the loss of endothelial vasodilators, especially NO; however, 
this mechanism does not appear to contribute to sex differences in the reactivity of the 
rat aorta to U-46619. Studies with human omental arteries also showed that neither 
inhibition of NOS with N-nitro-L -arginine nor removal of the endothelium affected 
contractile response to U-46619 (247). Finally, estrogen also may influence downstream 
signal transduction mechanisms involved in the thromboxane-induced VSM contraction. 
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The present study demonstrated that the potentiating effects of estrogen on 
contractile responses of the female aorta to VP involve upregulation of COX-2 activity, 
thereby enhancing production of TxA2 and potentiating vascular reactivity to TxA2. The 
greater contractile responses of the female aorta to VP also may be due to the 
upregulation of VP receptors in VSM cells by estrogen. Estrogen significantly increases 
the expression of VP V1α receptor mRNA in the preoptic area of young OvX rats (71). 
Similarly, estrogen increases VP V1 receptor expression in rabbit myometrium and in rat 
mesenteric arterioles (152, 229). In the latter study, upregulation of VP V1 receptors was 
correlated with an increase in the vasoconstrictor responses to VP in the isolated, 
perfused mesenteric vascular bed. Estradiol also increases the maximal response to VP 
and the density of VP binding sites in the mesenteric vasculature of male rats (229). In 
present study, OvX reduced maximal contractile response to VP by 55%, which was 
greater than the effects of Indo or NS (43% and 41% respectively). Thus, it is possible 
that OvX not only decreases constrictor prostanoid function, but also reduces the 
expression of VP binding sites by aortic VSM cells. 
 
5.5. Effects of phytoestrogens on vascular responses to VP and TxA2
The present study revealed that depletion of phytoestrogens from rat chow 
attenuates the contractile response to VP and TxA2 in OvX-female aorta. This finding is 
consistent with previous studies, which demonstrated that phytoestrogens could interact 
with the estrogen receptor, and exert estrogen-like effects (2, 40, 59). Indeed, 
phytoestrogens were reported to interact with COX and thereby regulate prostanoid 
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biosynthesis (54). Thus, in present study, phytoestrogens are likely responsible for the 
continued release of TxA2 in the OvX-female rat aorta, and masking the effects of OvX 
on vascular reactivity to VP and U-46619; however, adequate testing of this hypothesis 
will require further studies.  
 
5.6. Effects of estrogen on expression of COX and TxS mRNA and protein 
In the present study, the expression of COX-2 mRNA and protein were higher in 
female than in male rat aorta. OvX attenuated and estrogen replacement therapy restored 
the expression of both mRNA and protein. In contrast, estrogen had no effect on 
expression of COX-1 mRNA or protein in the female rat aorta.  The present findings are 
supported by previous studies, which suggest that estrogen may regulate vascular 
reactivity by upregulation of COX-2 and prostanoid production. For example, in cultured 
vascular endothelial cells, estrogen induces both COX-2 gene expression and new COX-
2 protein synthesis, resulting in increased production of PGI2 and PGE2 (189). Similarly, 
estrogen enhances PGI2 production in human umbilical vein endothelium cells by 
increasing COX-2 but not COX-1 expression (4). Thus, both past and present studies 
involving measurements vascular reactivity, prostanoid release, and gene expression 
consistently support the idea that estrogen enhances prostanoid-potentiated contractile 
responses to VP in female rat aorta by upregulating COX-2 activity. 
The present study also demonstrated that estrogen enhances the expression of 
TxS mRNA and protein expression in the female aorta. Although TxS inhibition in some 
previous studies failed to attenuate constrictor prostanoid-potentiated vasoconstriction 
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(70), as discussed above, the use of a TxS inhibitor will result in the accumulation of the 
upstream intermediate, PGH2, which is also a vasoconstrictor and acts on the same 
receptor as TxA2. Thus, the failure of the TxS inhibitor to attenuate vasoconstriction 
establishes the involvement of PGH2, but cannot exclude the involvement of TxA2 in 
potentiating contractile responses of the female aorta to VP. 
The present study also revealed that TxS mRNA is expressed in both 
endothelium and VSM, and that OvX attenuated and estrogen replacement therapy 
restored TxS mRNA expression in both endothelium and VSM. Estrogen also enhanced 
TxS protein expression both in the endothelium and VSM. Although previous studies 
have already revealed that COX-2 mRNA and protein are expressed in cultured vascular 
endothelium (182, 187, 189) and cultured VSM cells (182), the present study is the first 
to establish the expression of TxS mRNA and protein in both the endothelium and VSM 
of intact systemic blood vessels. Previous studies reported the production of TxA2 from 
cultured vascular endothelium but not VSM (79, 81); however, preliminary studies in 
this doctoral research revealed that TxA2 is released from both Endo+ and Endo- (VSM) 
aortic rings (data not shown), which is consistent with the molecular findings that both 
COX-2 and TxS are expressed in both endothelium and VSM cells of the female rat 
aorta. 
 
5.7. Effects of estrogen on thromboxane receptor expression 
In the present study, it was determined that TP mRNA is expressed in aortic 
VSM cells, and that expression is higher in female than in male aorta. Further, OvX 
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attenuates and estrogen replacement therapy restores TP mRNA expression in VSM cells. 
These findings are consistent with the present finding that contractile responses to U-
46619 are higher in female than in male aorta, and are attenuated by OvX in the female 
aorta and with the previous finding that the contractile responses to U-46619 in isolated 
rat lung are enhanced by estrogen (65). Thus, the present findings reveal that estrogen 
potentiates contractile responses of the female aorta to VP by enhancing the production 
of and the reactivity to TxA2. Further, this effect of estrogen involves upregulation of 
both message and protein expression of COX-2 and TxS. 
 
5.8. Clinical significance of present study 
Under normal physiological conditions, there are a variety of male-female 
differences in cardiovascular function. For example, basal blood pressure (125, 261), 
production of NO (91, 121), and vascular reactivity to VP, PE, U-46619 (65, 70, 117), 
all exhibit sexual dimorphism. The results from the present study advance our 
knowledge of male-female differences in cardiovascular function under normal 
condition and the role of estrogen in the sexual dimorphism present in cardiovascular 
function. Estrogen modulates prostanoid pathway function in the systemic vasculature 
by upregulating the expression of both COX-2 and TxS, resulting in increased 
production of TxA2 and PGI2. It also upregulates the expression of TP and thereby 
potentiates vascular reactivity to the constrictor prostanoids TxA2 and PGH2. 
The findings of the present study are consistent with the extensive 
epidemiological data that reveal the existence of prominent sexual dimorphism in the 
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incidences of primary vascular diseases that involve excessive vasoconstriction. Primary 
pulmonary hypertension (73, 252), migraine headache (194), and Raynaud’s disease (14, 
25, 87, 251) all occur in premenopausal women at rates as much as fourfold higher than 
in men. Further, an association has been reported between Raynaud’s disease and these 
other afflictions, suggesting that a common mechanism of vasospasm may be involved 
(236). Elevated vascular production of TxA2 may be the common mediator of vasospasm 
in all of these diseases. The production of this constrictor prostanoid is increased in 
patients with Raynaud’s disease (208), migraine headache (127), and pulmonary 
hypertension (37). Animal studies also have revealed the relationship between TxA2 and 
the development of these diseases (30, 67). Further, TxS inhibitors such as CGS13080 
and dazoxiben have been used successfully in the treatment of primary pulmonary 
hypertension and Raynaud’s disease (18, 198). 
The higher incidences of peripheral vascular diseases in premenopausal women 
than in men suggest that estrogen and/or other ovarian steroids may be involved in the 
pathogenesis of primary vascular diseases in women. Indeed, the recent Heart and 
Estrogen-progestin Replacement Study (HERS) reported no overall benefit of estrogen 
replacement therapy, and untoward cardiovascular events, including venous thrombosis, 
actually increased significantly in the first year of the study (94, 95, 105). Furthermore, 
oral contraceptive use in young women is also associated with an increased risk of 
thrombosis (17, 52) and acute myocardial infarction (AMI) (111). The increased 
production of TxA2 in the systemic vasculature with estrogen replacement therapy, as 
established in the present study, may underlie these deleterious effects of estrogen on the 
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cardiovascular system. Indeed, postmenopausal women undergoing estrogen 
replacement therapy have elevated urinary levels of TxA2 (249). Interestingly, the 
present study demonstrated that estrogen upregulates the release of TxA2 by increasing 
the expression of message for COX-2 and TxS, and the expression of COX-2 and TxS 
protein. These findings raise the intriguing possibility that the deleterious effects of 
estrogen on vasculature function and/or thrombosis, suggested by earlier (94, 95, 105) 
and more recent HERS II epidemiological studies (113, 215), may involve the effect of 
estrogen to potentiate activity of TxA2 and the constrictor prostanoid pathway function. 
VP is a potent vasoconstrictor that increases blood pressure and systemic 
vascular resistance. It has been used in the treatment of vasodilatory shock seen in sepsis, 
systemic inflammatory response, hypovolemia, cardiac arrest, polytrauma (35, 134), and 
for esophageal variceal bleeding in patients with liver cirrhosis (142). As an antidiuretic 
hormone, it is also been used to control the loss of water associated with diabetes 
insipidus (160). However, clinical trials assessing the safety and efficacy of VP use are 
limited, and male-female differences in the responses to clinical uses of VP are unknown. 
The present study provides clear evidence that vascular responsesiveness to VP is 
remarkably higher in females than in males, and that estrogen potentiates constrictor 
responses to VP in the female vasculature by upregulating COX-2 function and VP-
stimulated TxA2 production. Since TxA2 produces vasoconstriction and platelet 
aggregation, TxA2-mediated effects of VP administration need to be considered, 
especially in female patients. Indeed, it was reported that a 46 year-old female patient 
who recovered from acute respiratory distress syndrome following development of 
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septic shock, experienced severe ischemic necrosis of the skin and soft tissue 
surrounding the catheter site following administration of VP to treat the septic shock 
(115). The present study draws attention to possible side effects of VP as a potent 
vasoconstrictor used in clinical settings. The prominent male-female differences in VP-
induced vasoconstriction and activation of the TxA2 pathway suggest that different 
strategies may be needed for clinical uses of VP in male versus female patients. VP is 
also an important mediator during the development of heart failure. Plasma VP 
concentrations are significantly and chronically elevated in patients with heart failure, 
particularly in those with significant cardiac decompensation and hyponatremia (82, 83). 
VP contributes to the development of heart failure by preventing free water excretion 
and by inducing vasoconstriction. VP antagonists have been used in the treatment of 
heart failure (82). The findings of the present study suggest an additional role of VP in 
the development of heart failure which involves VP-stimulated constrictor prostanoids, 
particularlly in both male and female patients, and also imply that endogenous elevations 
in VP levels may have more deleterious effects in females than in males because of the 
combination of direct and TxA2-mediated effects on the cardiovascular system. 
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CHAPTER VI 
CONCLUSIONS 
 
In conclusion, the present studies demonstrated that sex differences exist in the 
contractile responses of the Sprague-Dawley rat aorta to VP and U-46619, and that 
estrogen potentiates contractile responses of the female rat aorta to VP and U-46619 by 
upregulating the expression of COX-2, TxS and TP mRNA, as well as the protein 
expression of COX-2 and TxS. These effects of estrogen enhance both the production of 
and reactivity to TxA2 by the female rat aorta.  
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